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I have come that they may have life,  




The antiphospholipid syndrome (APS) is a highly heterogeneous disease that presents with 
obstetric complications and/or thromboembolic events that can hit any side of the vascular 
tree in an unpredictable way. The common trait among all patients affected by the syndrome 
is the persistent presence of the antiphospholipid antibodies (aPL) and/or a prolonged 
coagulation time in vitro, the lupus anticoagulant (LA) test.  
The pathogenesis of APS has not yet been clearly defined. Many molecules are involved in 
the maintenance of the equilibrium called hemostasis, interacting and cross-reacting in an 
incredibly perfect orchestrated balance that somehow, in APS, is broken. The aim of this 
thesis has been to try to shed some light on the complex mechanisms behind APS, by 
focusing on some of the many pieces of the puzzle that characterize the disease. The 
complement, coagulation and fibrinolytic systems have been the subjects of this fascinating 
journey, and two proteins in particular have been on focus: C4b-binding protein (C4BP) and 
Thrombin activatable fibrinolysis inhibitor (TAFI). These are both regulators of complement 
activation that at the same time play a role in coagulation. Moreover, the link between 
myocardial infarction (MI) and aPL/LA has been explored. 
Paper I: TAFI and its activated form, TAFIa, were studied in patients affected by mainly 
primary APS (i.e. without other autoimmune diseases) and compared with a healthy control 
group. Moreover, C5a, a marker of complement activation, and markers of fibrinolysis were 
investigated and correlated with TAFI and TAFIa. Both TAFI and TAFIa are significantly 
higher in APS compared to controls. TAFIa is increased in APS patients affected by arterial 
thrombosis compared to other clinical manifestations, independently of traditional 
cardiovascular risk factors. TAFI is positively correlated with C5a, confirming its increase 
upon inflammation. TAFIa positively correlates with thrombomodulin, marker of endothelial 
damage/activation. The values of the clot lysis time (CLT) and of the permeability coefficient 
confirm impaired fibrinolysis in APS, with clots more resistant to lysis. 
Paper II: we investigated the prevalence of aPL in a large and well-characterized cohort of 
patients after 6-10 weeks from a first MI, and compared it with age, gender and region 
matched controls. We demonstrated ten times higher prevalence of aPL of the IgG isotype in 
patients versus controls, independently of traditional cardiovascular risk factors, suggesting 
that IgG aPL positivity may be considered a potential risk factor for MI in the general 
population. No significant differences were observed for IgM and IgA isotypes.   
 
 
Paper III: C4BP was investigated in a large cohort of patients affected by systemic lupus 
erythematosus (SLE), in primary APS and in controls. C4BP is lower in patients persistently 
positive for aPL and in patients treated with warfarin. C4BP correlates with markers of 
complement activation. Both persistent aPL positivity and warfarin are associated with C4BP 
reduction, and by means of a mediation analysis we were able to assess the relative 
contribution of these two variables: aPL have a direct reducing effect on C4BP of 11%, while 
warfarin contributes to 9% of the observed reduction. 
Paper IV: After the results of paper III, we decided to study the effect of warfarin on 
complement and C4BP in the general population, comparing it with the direct oral 
anticoagulants (DOACs), during and after treatment discontinuation. Warfarin, as opposed to 
DOACs, is associated with increased markers of complement activation, which persist for at 
least three weeks after withdrawal. Higher C4BP levels characterize the patients after 
warfarin discontinuation, as a rebound effect. DOACs have no effect on complement, but, in 
contrast, we demonstrate that warfarin is associated with complement activation, partly but 
probably not only through inhibition of C4BP. This study is of relevance in the context of 
APS, since different anticoagulant mechanisms have been subjects of debate in recent years. 
In conclusion, as also Ames stated regarding paper I1, this thesis has tried to insert other 
linking pieces in the puzzle of APS. We confirm the presence of impaired fibrinolysis and 
complement activation in APS, and we have opened the path for a new era of research in the 
syndrome, where also the treatment with anticoagulants has to be considered for its potential 
impact on complement activation. Moreover, although causality could not be proven, we 
demonstrate that the prevalence of aPL after myocardial infarction in the general population 
is considerable and higher than generally anticipated.   
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1.1 The Antiphospholipid Syndrome 
The Antiphospholipid syndrome (APS) is defined by arterial, venous, small vessel thrombosis 
and/or obstetric morbidity together with confirmed positive tests for autoantibodies of the IgG 
and IgM isotypes targeting β2 glycoprotein I (β2GPI), cardiolipin (CL) or positivity in the 
functional lupus anticoagulant test (LA)2. APS is also associated with other “non-criteria” 
features, such as thrombocytopenia, heart valve disease3, neurological, cutaneous, renal 
disorders, ocular problems and diffuse alveolar hemorrhage4-6. Primary (p) APS refers to the 
development of the syndrome independently of other autoimmune disorders, whereas secondary 
(s) APS is defined by the concomitant presence of other rheumatic diseases, most frequently 
Systemic Lupus Erythematosus (SLE).  
By definition, the disease is diagnosed when a thrombotic or obstetric event has already 
occurred, so the major therapeutic challenge is to avoid further events (secondary prevention).  
In case of SLE or in the presence of non-criteria manifestations, primary prevention can also be 
an issue. Therefore it is important to be able to identify those patients that are at increased risk 
for future thrombotic or obstetric events, so that closer monitoring and earlier treatment can be 
applied.   
1.2 History and classification criteria 
The first detection of the antiphospholipid antibodies (aPL) occurred by chance, when August 
Paul von Wassermann developed a first test for the detection of syphilis, based on complement 
fixation, in 1906. Spirocheta pallida had been identified just the previous year, and there were 
no available direct microbiological tests at the moment. He had the idea of detecting 
complement activation in serum of patients affected by the infection, in response to the 
formation of antigen-antibody complexes, after introducing the antigen. The antigen used was 
initially derived from the causative agent Treponema Pallidum, later replaced by bovine tissues 
with similar results. In 1941 cardiolipin was identified as antigen. Cardiolipin is a phospholipid 
extracted from the heart or muscles of bovines. Patients with antibodies for syphilis tested 
positive for the so-called “Wasserman test”, but it soon became clear that also some patients not 
affected by the infection were positive for the Wasserman reaction (WR), or for the later 
employed Venereal Disease Research Laboratory (VDRL) test for syphilis. Later on, it was 
demonstrated that these patients had antibodies against cardiolipin, but no syphilis infection. 
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In 1952 Moore and Mohr tried to understand and explain the reasons behind false positive 
serologic test results. They identified autoimmune diseases such as SLE, Rheumatoid arthritis 
and Sjögren’s syndrome as conditions associated with a persistent (> 6 months) false positivity 
for the syphilis tests. In the same year Conley and Hartman reported two cases of hemorrhagic 
disorders associated with SLE and the presence of a so-called “circulating anticoagulant”. 
Subsequent research in the fifties demonstrated an association between false positive WR tests 
and patients affected by SLE who had prolonged clotting times in vitro, which were not 
corrected by the addition of healthy donor plasma.  
In 1963 Bowie et al identified the paradoxical association between thrombotic events and the 
circulating anticoagulant. In 1972, Feinstein and Rapaport coined the name “Lupus 
Anticoagulant (LA)” to define this phenomenon of prolonged clotting time in phospholipid-
dependent assays. In the early 70s, Feinstein and Schleider observed that, by adding 
phospholipids to the in vitro clotting mixtures, the clotting time tended to normalize, and vice 
versa, by reducing the phospholipid content, the effect of LA was potentiated.   
In 1983 Harris et al7 described the first radioimmunoassay, then ELISA (see also 1.7.3), for the 
detection of anticardiolipin antibodies (aCL), with a 200 to 400-fold higher sensitivity than the 
precipitation method of the VDRL. In the same year, Hughes et al8 wrote about the strong 
correlation between LA and aCL with thrombosis, spontaneous abortions and neurological 
abnormalities, especially (but not only) in patients affected by SLE. 
In 1986 Hughes, Harris and Gharavi gave the first definition of “The Anticardiolipin 
Syndrome”9, coined to link thrombosis and other typical clinical manifestations with the 
presence of aCL/LA. 
Another major advance took place in 1990, when β2GPI was discovered to be the main 
“cofactor” for the binding of aPL to cardiolipin on ELISA plates10-12. 
Two sets of classification criteria have been developed to define APS, referred to as the Sapporo 
criteria (1999)13 and the Sydney criteria (Miyakis 2006)2. These criteria also define cut-offs and 
laboratory techniques to correctly identify the antibodies7,14-18. Therefore, when comparing 
actual with previous studies, it is important to take into account which set of classification 
criteria is used and also the methods employed to measure aPL/LA in the study of interest. 
The main upgrades brought by the more recent Sydney criteria are the following:  
 the stratification of APS patients according to the presence or absence of other risk 
factors for thrombosis/CV disease, together with older age (>55 men, >65 women) to 
avoid misclassification bias (more than 50% of APS patients have such risk factors) 
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 the addition of anti-β2GPI IgG/IgM 
 the introduction of a clear, quantifiable threshold for positivity at 99th percentile or >40 
GPL/MPL (see 1.7.3), instead of moderate-high 
 the sub-classification based on positivity for multiple vs single aPL and for which 
isotype/antigen 
 the introduction of a temporal interval between aPL determination and clinical event 
that should be at least 12 weeks but no more than 5 years 
 the prolongation of the interval to confirm persistence presence of aPL to 12 instead of 6 
weeks, in order to increase specificity 
 the introduction of clearer definitions of other features associated with APS, although 
these are still considered “non-criteria features” because of insufficient evidence of 
association with aPL 
1.3 Epidemiology 
The exact prevalence and incidence of APS are still unknown, but a recent estimate by 
Duarte-García et al19 has been 50 cases (95% CI: 42-589) per 100 000 persons and 2.1 new 
cases (95% CI: 1.4-2.8) per 100 000 persons/year respectively, with no significant 
difference between men and women. 
aPL are present in 30-40% of SLE patients and they are associated with thrombosis in circa 
one third of SLE-aPL+ (10-15% of total SLE)20.  
Information on epidemiologic characteristics of the disease have been described in specific 
disease cohorts, such as SLE patients21 or through the Euro-Phospholipid project by Cervera 
et al22-26, an observational study including 1000 APS patients from 13 European countries. 
This project could take place thanks to the efforts of the European Forum on 
Antiphospholipid Antibodies, a network of centers devoted to perform international 
collaborative studies on aPL. Therefore, since data have been gathered mainly by 
rheumatologists from a highly selected cohort, overestimations are possible. Data collection 
started in 1999, followed by two follow-up studies after 5 and 10 years, the last one 
published in 2015. The female-to-male ratio among patients with primary APS was 5, which 
decreased to 3.5 after excluding patients with SLE, and to 1.0 after excluding obstetric APS. 
The most frequent clinical manifestations at inclusion were DVT (38.9%), thrombocytopenia 
(29.6%), stroke (19.8%), pulmonary embolism (14.1%). During a 10-year follow-up, 
thrombocytopenia (8.7%) and stroke (5.3%) occurred most commonly. Early pregnancy loss 
was the most common obstetric manifestation (35.4%).  
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Regarding the mortality rate, 9.3% patients died in 10 years of follow-up, divided into 5.3% 
in the initial 5 years and 4% in the following 5 years follow-up. The unadjusted Standardized 
Mortality Ratio (SMR) for the total cohort, defined as the observed number of deaths over 
those expected from the general population of the studied area, was 1.8 (95% CI 1.5 to 2.1). 
The major causes of death during the 10-year period of observation were bacterial infections 
(21.5%), myocardial infarctions (MI) (13.9%), malignancies (13.9%), strokes (11.8%) and 
hemorrhages (10.7%).  
The overall frequency of mortality of APS patients reported by Duarte-Garcia et al19 in the 
period 2000-2015 was not notably different from that observed in the general population 
belonging to the same geographic region (SMR 1.6, 95% CI 0.74-3.05). Nevertheless, they 
reported a lower 5 and 10-year survival rate compared to Cervera et al25, probably attributed 
to the fact that their inception cohort was older.  
1.4 Catastrophic Antiphospholipid Syndrome (CAPS) 
Catastrophic APS (CAPS) was described in 1992 by Asherson27 as a life-threatening form 
characterized by rapidly occurring thrombosis, often affecting the microcirculation, in three 
or more organs, in the presence of aPL28-31. The preliminary classification criteria were 
issued in the occasion of the 10th international congress on aPL held in Taormina in 2002. 
Definite CAPS is defined when all the following four criteria are met: 1. Evidence of 
involvement of three or more organs, systems and/or tissues, 2. Development of 
manifestations in less than a week or simultaneously, 3. Confirmation by histopathology of 
small vessel occlusion in at least one organ or tissue, 4. Laboratory confirmation of the 
presence of aPL/LA. Probable CAPS is considered if only two targets are affected, if small 
vessel occlusion cannot be confirmed by histopathology, or if the third event develops in 
more than a week but less than a month despite anticoagulation, or if a patient is aPL+ but 
has never been tested before. CAPS belongs to the spectrum of the Thrombotic 
Michroangiopatic Syndromes, together with Thrombotic Thrombocytopenic Purpura (TTP), 
Disseminated Intravascular Coagulation (DIC), Heparin-Induced Thrombocytopenia (HIT), 
Hemolysis-Elevated Liver enzymes-Low Platelets (HELLP) and the newly discovered 
Covid-19 related thrombotic disorder. It affects ca 0.8% of APS cases and it has a very high 
mortality, because of multiorgan failure. It is important to underline that the mortality rate 
has decreased during the last decade (from 50% to 37%)32, because of treatment 
improvements. This could be achieved thanks to the efforts of the European Forum on aPL 
that, in 2000, decided to start to collect data on CAPS cases from different European centers, 
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given the rarity of the syndrome and the difficulty to gather representative data from a single 
center. This gave life to the CAPS Registry, an international registry of patients with 
catastrophic APS. From this registry we have learnt that many CAPS patients have 
precipitating factors. Such factors were identified in ca 65% of cases, and the most 
commonly reported are infections (49%), surgery (17%), cancer (16%). The organs most 
often involved are the kidney (73%), the lungs (66%) in the form of acute respiratory distress 
syndrome (ARDS) or pulmonary embolism (PE), and the central nervous system (56%) 
where stroke and encephalopathy are common.  
1.5 Pathogenesis 
Both environmental and genetic factors contribute to susceptibility to the syndrome.  
As far as genetic predisposition is concerned, an association between the HLA system and 
aPL production has been reported in different studies33-35. HLA-DRB1*07, HLA-DRB1*04, 
HLA-DRB1*13, HLA-DQB1*0302 polymorphisms are some examples of HLA class II 
alleles associated with aPL.  
The HLA system plays a role in antigen presentation from antigen presenting cells to effector 
T-cells, that in turn activate B-cells to produce antibodies directed against those antigens, for 
example β2GPI. Other polymorphisms potentially associated with APS have been found in 
target antigens, coagulation factors, or complement inhibitory proteins36-39. The gene 
encoding for β2GPI is located on chromosome 17q23 and some polymorphisms of single 
nucleotides have been associated with anti-β2GPI production, the most popular being at 
position 247, confirmed by different studies40-43, but not by all44. This single nucleotide 
change results in one amino acid substitution, the expression of Valine rather than Leucine, 
in domain V of the protein. This and other polymorphisms have been suggested to increase 
the antigenicity of the protein, leading to antibody production45. 
Environmental factors that have been associated with APS are infections46, previous 
smoking47, oxidative stress48, trauma, vaccinations, drugs, increased apoptosis, e.g. during 
elevated cell turnover as in cancer, or in conditions of decreased clearance as in SLE. 
Infections can trigger B-cells to produce aPL through molecular mimicry, a cross-reaction 
between epitopes of infectious agents and β2GPI
49,50. Some aPL can also be considered 
natural autoantibodies, defined as immunoglobulins present in the absence of exogenous 
antigen stimulation, that play a role in the innate immune system. aPL are known to increase 
transiently during infections51 and may become pathogenic in case of adverse conditions, e.g. 
oxidative stress45. Transient aPL, i.e. aPL not confirmed by a second determination, are 
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generally not believed to be associated with thrombosis and consequently they are not 
considered a reason for anticoagulation. However, no studies have assessed the risk of 
thrombosis during the presence of transient antibodies52. This assumption should therefore be 
questioned as e.g. suggested by de Groot and Urbanus53. 
Apoptotic cells express phosphatidylserine on the outer membrane leaflet, so that 
phospholipid-binding proteins can bind. In case of excess of apoptosis or dysregulation in 
clearance of apoptotic cells, aPL production may be induced by an excess of antigen54,55. A 
mechanism can be due to maturation of antigen-presenting cells (dendritic cells) that 
stimulate T-helper cells, followed by subsequent B-cells antibody production against 
phospholipid-binding proteins56. Moreover, aPL may promote Fc receptor-dependent 
phagocytosis, which may have pro-inflammatory sequelae57, among which is the activation 
of complement via the classical pathway. 
The possible antigenic targets for aPL are58,59: 
 the main antigens: β2GPI (also in complex with oxLDL), phospholipids (e.g. 
vimentin, phosphatidylethanolamine, phosphatidylserine, cardiolipin, 
phosphatidylinositol) 
 natural anticoagulants: protein C, protein S (also in complex with C4BP), 
annexin II and V60, tissue factor pathway inhibitor (TFPI), antithrombin (AT)  
 proteins of the fibrinolytic system: tissue plasminogen activator (tPA), plasmin 
 coagulation factors: fXII, fXI, fVII, fV, high-molecular weight kininogen 
(HMWK), prothrombin (fII), thrombin (fIIa) 
Some of these proteins are serine proteases that share epitopes with β2GPI in their 
catalytic domains.  
Βeta2 glycoprotein I (β2GPI) is by many believed to be the predominant and specific 
antigenic target in APS61. The β2GPI molecule is a single chain, highly glycosylated 
glycoprotein of 54 kDa molecular weight. It circulates in plasma at a concentration of 
200μg/ml, of which 40% is bound to lipoproteins. It is produced by the liver, 
trophoblasts, endothelial cells, monocytes and platelets. It consists of 326 amino acids, 
organized into five domains, also called Short Consensus Repeats (SCR) or 
Complement Control Protein (CCP) modules. Domain V is made of 80 amino acids and 
it is found at the carboxyl-terminal, whereas domain I to IV are composed of 60 amino 
acids each and contain the amino-terminal portion of the glycoprotein. Domain V is an 
atypical SCR that contains a lysine-rich sequence, positively charged, that facilitates the 




and activated platelets with high affinity, through charge interactions. The affinity of 
β2GPI to phospholipid surfaces is low, but increases by 100-fold in the presence of anti-
β2GPI. β2GPI belongs to the Complement Control Protein (CCP) family, therefore it has 
both anticoagulant and complement regulatory functions (see section 1.10.4), and can 
assume different conformations63 depending on pH, temperature, oxidative stress. It 
circulates in plasma in a closed, ring-like conformation, through the binding of Arginine 
(Arg)39 and Arg43 in domain I to Lysine (Lys)305 and Lys317 in domain V. When domain 
V is instead associated to negatively charged phospholipids, β2GPI assumes a fish-hook 
like conformation, thereby exposing the cryptic epitope (Arg39 and Arg43) on domain I64 
(figure 1). When two molecules of β2GPI are close to each other in the open 
conformation, they attract aPL, that bind and dimerize the protein, fixing it in an active 
conformation, with increased immunogenicity65.  
 
Figure 1 – β2 Glycoprotein I 
Model of the conversion of β2GPI from closed and circular on the left, into an open, hockey-
stick like conformation on the right, assumed after binding to phospholipids. The latin 
numerals indicate the different domains, or CCPs/SCR. Note that the antibody-binding site 








Cell activation: it has been demonstrated that aPL are able to activate endothelial cells 
(ECs), monocytes, platelets (PLTs), and neutrophils, through intracellular signaling20,66-
70. aPL, after binding to their target receptors, different for different cells, are transported 
to the nucleus via endosomal uptake, with different endocytic routes according to the 
cell type71. Once there, the complexes aPL-receptor are able to induce protein synthesis 
through other mediators in the intracellular signaling pathways, such as the adapter 
molecule Myeloid differentiation factor 88 (MyD88)72, with subsequent activation and 
translocation of Nuclear factor-κB (NFkB) from cytoplasm to the nucleus (the same 
signaling molecules implicated in lipopolysaccharides or IL-1 cascade in endothelial 
cells) or through the activation of p38 mitogen-activated protein kinase (p38MAPK)73, 
with subsequent phosphorylation of cytosolic phospholipase A2 (mainly in platelets)74. 
The activated cells express pro-coagulant/pro-inflammatory phenotypes that contribute to 
create a milieu prone to thrombosis.  
Endothelial cells express Annexin II, a membrane-bound receptor for tissue 
plasminogen activator (tPA) and plasminogen, that lacks a transmembrane domain to 
intracellular pathway signaling. Annexin II has pro-fibrinolytic properties because it 
enhances tPA-dependent conversion of plasminogen into active plasmin at the 
endothelial cell surface, even in the absence of fibrin75. β2GPI in its monomeric form 
can bind to Annexin II76, targeting ECs for activation by aPL77. Other receptors that 
have been reported to act as mediators in β2GPI-induced endothelial cell activation are 
Toll-like receptors (TLR) 278 and 479, pro-thrombotic and pro-inflammatory molecules 
that usually bind to microbial structures, but can also bind to β2GPI.  
Once activated, ECs express Tissue Factor (TF), pro-inflammatory cytokines, and 
adhesion molecules, such as Intercellular Adhesion Molecule 1 (ICAM-1), Vascular cell 
adhesion protein 1 (VCAM-1) and E-selectin80. 
Monocytes, once activated, mostly via Toll-like receptors 2 and 8, increase TF 
production, expression and release in plasma81. TF is an inducible glycoprotein that 
triggers the extrinsic coagulation pathway, through binding with fVII on the cell surface. 
A study by Cuadrado et al82 demonstrated, by flow cytometry, that patients with primary 
(p)APS, especially those who are IgG aCL positive (+), have higher levels of TF 
expressed on the surface of monocytes, and also in plasma, compared to aPL-carriers, 
patients affected by thrombosis lacking aPL and healthy controls. pAPS patients also 
express more TF-related pro-coagulant activity on intact cells and cell lysates, as 
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showed by a chromogenic assay. No difference related to anticoagulant treatment was 
recorded. These results were confirmed by other groups83.  
Platelets (PLTs) are activated by the binding of aPL to phosphatidylserine and Low-
Density Lipoprotein (LDL) receptor-related protein 8 (LRP8), also called 
Apolipoprotein E Receptor 2’ (ApoER2’). β2GPI directly binds to Glycoprotein Ibα 
(GPIbα)84, a receptor for von Willebrand factor (VWF), among others85, making it less 
available for platelet aggregation. Anti-β2GPI, through competitively binding to β2GPI, 
are supposed to activate platelets also through the increased availability of GPIbα for 
VWF, that derives from less β2GPI binding to GPIbα
86. Once activated, PLTs increase 
expression of glycoprotein IIb/IIIa (GPIIb/IIIa) and Thromboxane (TX) A2, the major 
eicosanoid produced by platelets with potent pro-aggregant and vasoconstrictor 
activities87. 
Anti-β2GPI can activate neutrophils through TLR4 and reactive oxygen species 
formation. Activated neutrophils play a role in both inflammation and coagulation 
through NETosis (Neutrophil Extracellular Traps)88. NETs are a network of extracellular 
fibers released by neutrophils with the aim of catching microorganisms, preventing them 
from spreading. They are made of nuclear and granular components like chromatin, 
histones, dsDNA, Myeloperoxidase (MPO), Neutrophil Elastase (NE), and other 
microbicidal enzymes89. NETs bind and activate platelets, TF and fVII, and inactivate 
TFPI, accelerating thrombus formation90. They also inhibit fibrinolysis. 
Activated ECs, PLTs and monocyte release microparticles (MPs). MPs are small 
vesicles (0.1-1μm), membrane-coated, released by exocytosis, that express anionic 
phospholipids (mainly phosphatidylserine), together with other surface antigens from 
the cell of origin. This phospholipid overexposure supports the assembly of clotting 
enzyme complexes with subsequent thrombin generation and increased thrombotic 
risk91-95, as well as binding of β2GPI
96,97. A recent study by our group97 reports that 
β2GPI expressing-MPs are less frequent in the subset of aPL+ as compared to aPL 
negative (-) SLE patients. The hypothesis is that anti-β2GPI bind to β2GPI on the surface 
of MPs, thus hiding them from macrophage recognition and clearance. Many studies 
show that MPs are increased in APS/aPL+ subjects as compared to controls, in 
particular Endothelial-derived MPs (EMPs) and Monocyte-derived MPs 
(MoMPs)94,95,98,99. Numerous circulating MPs are also a possible source of autoantigens 
that can trigger production of autoantibodies. Another pro-coagulant mechanism 
involves platelet-derived MPs (PMPs): because of the abundance of fVa receptors on 
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their membranes, they provide a large catalytic surface for the prothrombinase 
reaction96. Other studies show the possible regulatory functions of MPs93, e.g. when they 
mostly express Tissue Factor Pathway Inhibitor (TFPI), Endothelial cell Protein C 
receptor (EPCR), or Thrombomodulin (TM), or when PMPs bind to free protein S, 
stimulating APC binding, thus accelerating fVa inactivation100. The balance between 
pro-and anti-coagulant properties of MPs could be impaired by the presence of aPL, e.g. 
by binding to free protein S or to β2GPI-phosphatidylserine on MP surfaces. 
Dysregulation in hemostasis and inflammation represent the key mechanisms that 
foreshadow thrombosis. They depend on three enzymatic cascades that share close 
similarities in structure and function and relate tightly to each other by several crossover 
points: coagulation, fibrinolysis and complement1,101-106 (see also 1.10.1). 
Coagulation is enhanced by aPL-mediated platelet activation and increased TF production 
(see above). Moreover, aPL have been shown to inhibit natural anticoagulants such as 
protein S, protein C, annexin V60, antithrombin and TFPI, among others.  
Fibrinolysis may be impaired by interaction of aPL with annexin II and β2GPI that both bind 
tPA on endothelial cells and promote fibrinolysis107. Other postulated mechanisms to explain 
hypofibrinolysis in APS consist in the increased activity of plasminogen activator inhibitor 
type 1 (PAI-1)108, TAFIa, the presence of antibodies specifically directed against tPA108, 
plasminogen and plasmin109.  
Complement is triggered mainly through the classical pathway initiated by antibody-antigen 
binding. It can activate ECs either directly through sC5b-9, or indirectly by C5a receptor. 
C5a can also activate neutrophils, with consequent NET and TF release110. Complement 
boosts inflammation, it enhances the release of reactive oxidants, proteolytic enzymes, pro-
inflammatory cytokines. It induces trophoblast injury in pregnancy and can lead to fibrin 
deposition and thrombosis, by interacting with the coagulation system.  
Unresolved questions, hypothesis regarding pathogenic aspects of APS: The activation 
of cells and systems that are ubiquitous in the human body and the presence of aPL that 
circulate systemically may explain why APS is characterized by thrombosis in almost every 
vessel of the body, in both arteries and veins, large vessels and microcirculation, as well as in 
the placenta. Nevertheless, it is yet not explained exactly how the systemic presence of aPL 
results in local thrombosis, and biomarkers that are able to predict the specific clinical 
phenotype of each and every patient have not been discovered yet.  
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It is known that aPL are an heterogeneous group of auto-antibodies with different sub-
specificities111 and this might contribute to tilt the balance preferentially towards one clinical 
manifestation rather than another. Local factors are also important, like the endothelium. In 
fact, hemostasis derives from a finely tuned balance between pro- and anti-coagulant forces 
and the endothelium plays a key role in keeping this balance. The endothelium is an organ 
itself, highly heterogeneous, a metabolically active interface between blood and tissues. It 
responds with a different distribution of receptors and cell-specific signaling pathways to 
local factors, differently expressed in time and space throughout the vascular tree112,113, e.g. 
the extracellular milieu or even hemodynamic forces, namely the shear-stress and the cyclic 
strain, via mechanoreceptors. It is responsible for vasomotor tone through interactions with 
vascular smooth muscle cells and pericytes. It acts on vessel permeability, regulating the 
paracellular and transcellular exchange of fluids, ions and macromolecules between tissues 
and blood, as well as leukocyte adhesion and trafficking, recruiting them to areas of tissue 
damage via adhesion molecules and release of cytokines. It is crucial in regulating 
inflammation and hemostasis114. “If the arteries and veins of the body represent the interstate 
highways, and the capillaries the neighborhood streets, the endothelium may be thought of as 
the city sidewalk, brimming with life, commerce, and activity” (cit from Aird)113.  
Another research question in the pathogenesis of this disease is why the clinical phenotypes 
are so heterogeneous, i.e. why some individuals, despite being positive for aPL, remain 
asymptomatic, whereas others are hit by CAPS, the most severe form of the disease.  
The “second hit” hypothesis66 has been suggested to explain this clinical observation: a 
first hit, represented by the presence of aPL, alters the milieu in favor of a thrombophilic 
state, but a second hit that alters endothelial integrity e.g. infections, surgery, oxidative 
stress, complement activation, is necessary to trigger thrombus formation.  
APS clinical manifestations derive from a systemic imbalance that meets a local specific 
imbalance, as expressed by the old Virchow’s triad: a hypercoagulable state that interacts 





1.6 Obstetric Antiphospholipid Syndrome 
According to Miyakis classification criteria2, obstetric APS is defined by the same laboratory 
criteria as thrombotic APS, together with the presence of a history of three early consecutive 
miscarriages (< 10 weeks of gestation), and/or one miscarriage or stillbirth after 10 weeks of 
gestation, and/or one intra-uterine growth restriction or a premature birth before 34 weeks of 
gestation due to preeclampsia, eclampsia or placental insufficiency. Placental insufficiency is 
defined by abnormal or non-reassuring fetal surveillance test, abnormal Doppler flow 
velocimetry waveform analysis suggestive of fetal hypoxemia, oligohydramnios, and postnatal 
birth weight less than the 10th percentile for the gestational age.  
In order to be classified as APS, maternal anatomic or hormonal abnormalities, and paternal and 
maternal chromosomal causes of miscarriage should be excluded, and the fetus should be 
morphologically normal at ultrasound or by direct examination.  
Obstetric APS may be characterized by different pathogenic mechanisms than thrombotic 
APS115. In mice models, the injection of aPL IgG can cause fetal damage without the 
requirement of a second hit, provided that the complement system is intact116. In humans, a very 
recently published study by Pregnolato et al117 enlightens the association of even low titers aPL 
with APS obstetric complications, boosting the concept that thrombotic and obstetric APS may 
constitute distinct clinical entities. The biological explanation can be that β2GPI is not expressed 
on resting vascular endothelium, whereas it is abundant on trophoblasts20,118,119 even under 
physiological conditions. Moreover, thrombosis is not the main feature of obstetric APS120, 
although present. Some mechanisms leading to thrombosis consist in the ability of aPL to 
disrupt the annexin V anticoagulant shield on trophoblast monolayers60. Nevertheless, defective 
placentation and inflammation are considered the major causes of pregnancy morbidity in APS, 
leading to impaired feto-maternal blood exchange. This is mediated by the expression of a 
decidual inflammatory phenotype and trophoblast damage. Experimental studies show that anti-
β2GPI can trigger placental inflammation through TLR4/MyD88 signaling pathway in 
trophoblasts121. This leads to the inhibition of trophoblasts proliferation and invasiveness, 
defective Human Chorionic Gonadotropin release and increased apoptosis.  
Complement activation is also involved in placental inflammation (see section 1.10). It is 
still an open question if the predominant mechanism leading to complement activation is to 
be attributed to a dysregulation of complement inhibitory proteins or to an excess of 
complement activation products induced by aPL122. In fact, complement activation products 
are detected in normal placentas as well, but to a less extent and without associated tissue 
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damage, probably because of highly expressed complement regulatory proteins on 
cytotrophoblasts in healthy pregnancies.  
1.7 Associations between thrombosis and aPL/LA 
1.7.1 Prevalence of thrombosis in aPL/LA positive patients  
A clear answer to the question of the prevalence of thrombotic events in aPL/LA positive 
patients and which aPL are the best predictor for thrombosis is not easy to give. Studies so 
far have been very heterogeneous in terms of: 
 study design and enrollment/exclusion criteria 
 isotype of aPL considered 
 cut-offs and laboratory methods 
 temporal interval between confirmation of aPL/LA tests and between aPL/LA 
determination and thrombotic event 
 APS classification criteria (Sapporo or Sydney) 
 type (first/recurrent) and site (arterial/venous/microthrombosis) of thrombotic event  
 documentation/definition of thrombosis 
 associations with other autoimmune diseases (primary/secondary APS) 
 consideration of comorbidities or presence of other thrombotic/CV risk factors 
As far as study design is concerned, cross-sectional and case-control studies give information 
on the strength of association between the two variables of interest (aPL/LA and thrombotic 
events) but they cannot establish causality, because it is not known if aPL/LA were present 
before the event or if they became positive as a response to it. Moreover, the choice of 
controls should be from the same source population as the cases, in order to reduce bias. 
Longitudinal studies are better in this sense, because they can attempt to establish causality, 
since they provide a clear temporal sequence between aPL/LA determination and 
thrombosis. Still, unless measured quite often and not just twice as recommended, we cannot 
know if aPL are permanent, transient, if and why their titers fluctuate over time and what are 
the effects of that. It is still debated if transient aPL can be pathogenic123. 
A meta-analysis by Galli et al124,125, ranging from 1988-2000, concluded that positivity in the 
LA test is the strongest predictor of thrombosis, irrespective of the presence of SLE, or type 
and site of thrombotic event. Antibodies of the IgG isotype at higher titers are also more 
strongly associated with thrombosis, as compared to IgM. Some studies included in this 
review were longitudinal126-130. They showed higher rates of recurrent venous 
thromboembolism and sometimes even higher mortality rates129 after cessation of 
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anticoagulant treatments, in patients who were IgG aCL+ as compared to aPL negative 
patients affected by previous thrombosis.  
There is in general a consensus on the fact that triple positivity (TP), defined as the 
concomitant repeated presence of LA, aCL IgG or IgM and anti-β2GPI IgG or IgM, is a 
marker of higher risk for thrombosis131,132. A previous study by Pengo et al131, using the 
Sapporo criteria for the definition of APS, established an OR of 33.3 (95%CI 7.0-157.6) of 
thrombotic events in TP versus non-TP, adjusted for age, gender, other autoimmune diseases 
including SLE, and established risk factors for venous and arterial thromboembolism. A 
more recent prospective study133 showed a cumulative incidence of thromboembolism in TPs 
carriers of 37.1% (19.9-54.3%) after 10 years of follow-up. The thrombotic events were 
equally distributed between the arterial and venous circulation. The annual rate of first 
thrombotic event was calculated as 5.3% in TP carriers as compared to 1.4% in single aPL 
positives carriers134 and to 0.4% in the aPL negative general population in the age span 35 to 
55 years135. TP also present a higher rate of recurrences, even under anticoagulant therapy, as 
well as worse pregnancy outcomes136. TP has the highest specificity and positive predictive 
value for APS diagnosis137. 
LA has been considered so far a stronger predictor of thrombosis than the specific aPL tests 
in SLE124,125,138, but according to Pengo et al139 it should be present together with at least one 
other aPL positivity to be considered associated with thrombosis. Also in the setting of the 
Warfarin in the Antiphospholipid Syndrome (WAPS) study140, a prospective, multicenter, 
international study with the aim to compare standard vs high-intensity warfarin, an increased 
risk of prospective thrombosis was reported for LA+ patients who also belonged to the upper 
tertile of IgG anti-β2GPI and anti-annexin V titers.  
Anti-β2GPI are considered to have the highest sensitivity and negative predictive value for 
the diagnosis of APS137. They seem to be associated with thrombosis, in particular when 
coexistent with LA+. An explanation for this has been attempted by some research groups 
(see section on non-criteria aPL on anti-domain I β2GPI). Other data have shown that the 
presence of anti-β2GPI and aCL without LA positivity has a modest association with 
thrombosis and low recurrence rate, although a prospective study by Neville et al141 in 2009 
concluded that anti-β2GPI, in the concomitant absence of LA positivity, predict venous 
thromboembolism with HR 5.8 (1.4-24.1).  
 
 15 
Overall, the positivity of just one aPL is by some not even considered associated with 
thrombosis131,142. Therefore, as compared to single test, the analysis of a complete aPL 
antibody profile is clearly superior in the quantification of thrombotic risk in APS patients. 
Non-criteria aPL: In recent years, research has been directed towards trying to find some 
antigen sub-specificities or aPL isotypes that may increase the risk prediction for thrombosis, 
in order to better tailor treatment choices regarding type, intensity and duration of 
anticoagulation in the future. Some examples are anti-domain I β2GPI
143-147, anti-
prothrombin/phosphatidylserine antibodies (aPS/PT)148-153, anti-prothrombin (aPT), IgA 
aPL154 or other non-criteria aPL111.  
Anti-domain I β2GPI IgG
144,145,155 are considered by some the pathogenic antibodies. They 
recognize the epitope Gly40-Arg43 in the domain I in the NH2 terminal region of the 
molecule. It has been postulated that when anti-β2GPI and aCL tests are both positive, the 
anti-β2GPI assay may identify domain I. That’s because the anti-domain I β2GPI recognize 
the epitope just when β2GPI is in its open conformation, thus bound to cardiolipin in solid-
phase. Conversely, when anti-β2GPI test is positive in the absence of aCL positivity, the 
assay is probably detecting antibodies against other domains, because domain I is hidden 
when β2GPI is in circular conformation. Anti-domain I β2GPI IgG are also believed to 
generate LA activity, as they are more frequently detected when also LA test is positive. 
They are highly associated with thromboembolism. Conversely, the non-domain I anti-β2GPI 
IgG (anti-domain IV/V) are considered less or non-pathogenic because of their lack of 
association with thrombotic events, and they are more often found in isolated anti-β2GPI 
positivity145,156,157. 
aPS/PT are antibodies that recognize the complex phosphatidylserine/prothrombin as 
antigen. Their prevalence is estimated as 27-51% in pAPS, 47-53% in sAPS, 10-33% in 
APS-negative SLE158. A study in pAPS from 2017159 identified aPS/PT as strongly 
associated, in both titers and prevalence, with severe thrombotic and obstetric complications, 
as well as thrombotic microangiopathy and triple positivity. aPS/PT seem to correlate with 
the presence of other aPL and especially LA, raising the hypothesis that the test may be a 
surrogate for LA activity160. aPS/PT are also associated with other non-criteria APS features, 
such as thrombocytopenia or hemolytic anemia, although in lower titers and prevalence 
compared to thrombotic APS158. Quadruple positivity (the concurrent presence of LA, aCL, 
anti-β2GPI and aPS/PT) seems to confer an even higher risk (30-fold) for thrombosis than 
triple positivity161,162.  
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Another relevant aspect concerns which subclasses of IgG isotype163 present more 
association with thrombosis in APS and how the subclass distribution changes over time and 
disease activity. The subclass response is influenced by the environment (cytokines), the 
chronicity of antigen stimulation, and genetics. Generally speaking, IgG1 and IgG3 are 
activated by protein antigens mainly through T-cells, whereas IgG2 response is mostly 
activated by carbohydrate antigens. IgG2 and IgG4 are considered weaker in activating 
complement via the classical pathway59.  
In the study by Samarkos et al163, IgG2 seem to be more prevalent in anti-β2GPI, whereas 
IgG2 and IgG3 are more frequently elevated in aCL, although IgG1 aCL is the predominant 
subclass in terms of mean percentage levels.  
Further studies on the association between different aPL and thrombosis are needed. 
1.7.2 Prevalence of aPL/LA in thromboembolism 
Despite the difficulties in drawing definite conclusions, Andreoli et al, on behalf of the APS 
Alliance For Clinical Trials and International Networking (APS ACTION), tried to assess 
the frequency of aPL+ in the general population affected by thromboembolism, by reviewing 
120 papers published between 1984-2011164,165. The overall percentages (IQR) of prevalence 
of aPL+ that have been collected are the following: 13.5% (6.8-23.3) in stroke, 11% (4-23) 
in MI, 6% (2-13) in pregnancy morbidity and 9.5% (5.3-15.8) in DVT.  
Nevertheless, the authors pointed out several limitations:  
 60% of papers were published before 2000 
 all three aPL tests (anti-β2GPI, aCL and LA) were performed in just 11% of the 
papers, since the majority were published in early years of APS research, when anti-
β2GPI had not been yet recognized and were not even part of the old criteria 
 there was a lack of standardization of aPL tests: low titers aCL (<20 units) were 
considered positive in 36% of papers, anti-β2GPI had an heterogeneous cut-off and 
only 20% of the studies confirmed aPL+ by repeating testing 
 circa 50% of the studies had a retrospective study design 
 concomitant thrombotic risk factors were statistically evaluated in 45% of stroke 
studies, 43% of DVT papers and in 36% MI studies. Thus, it is not possible to 





1.7.3 Measurements of aPL/LA 
Since APS diagnosis depends strongly on the presence of aPL/LA, it is of outmost 
importance that they are correctly and consistently identified. With this purpose, the 
International society of thrombosis and hemostasis (ISTH)/Scientific and Standardization 
Committee (SCC) published updated guidelines for the laboratory identification of aPL/LA 
in 1991, 1995166, 2009167, 2020168,169. 
Lupus anticoagulant (LA)  
Three steps are necessary to identify LA:  
1. The screening test, with a phospholipid-dependent assay such as dilute Russell’s viper 
venom time (dRVVT) or a sensitive activated Partial Thromboplastin Time (aPTT) with 
silica as activator and low phospholipid concentration. Samples should be collected in 
sodium citrate 9:1 and subsequently double centrifugated at 2000-2500g for 15min at 
room temperature to obtain platelet-poor plasma, with a minimal number of residual 
platelets <107/ml. The test is suspected to be positive for LA when the clotting time is 
prolonged (>99th percentile of healthy donors). 
2. The mixing test, by adding plasma 1:1 from a pool of at least 40 adult healthy donors. If 
the clotting time normalizes, it indicates a natural or acquired deficiency of coagulation 
factors. If it is still prolonged, it strengthens the suspicion of LA positivity170.  
3. The confirmation step consists in adding phospholipid-containing reagents to reach a 
state of excess of phoshospholipids. If the clotting time now normalizes, it confirms LA 
positivity171.  
More than one screening test should be performed in order to increase the sensitivity of the 
assay. dRVVT and LA-sensitive aPTT are recommended. dRVVT is based on a viper venom 
that directly activates fX. aPTT tests can be more or less sensitive to LA, depending on the 
phospholipid content that triggers coagulation. The 2009 guidelines added the 
recommendation of testing for LA when there is a reasonable suspicion of APS as cause of 
thrombosis (high pre-test probability). In fact, the assays for LA determination have low 
specificity with consequent higher risk of false-positive results. False-negative results are 
also possible, for example when platelets, being a source of phospholipids, are not 
completely removed in the process of freeze-thawing172. 
Both false-negative and false-positive LA results can occur when testing patients on 
anticoagulant therapy and separate recommendations were written last year in order to 
minimize errors and guide LA detection in this setting169. False positive or negative results 
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can also occur during pregnancy. The recommendation in this case is to wait at least 6 weeks 
post-partum, ideally 3 months before performing the test. 
aCL and anti-β2GPI 
The first aCL test was established in 1983 by Harris et al7 as a radioimmunoassay using 
cardiolipin as antigen, diluting serum samples with a mixture of gelatin/phosphate buffered 
saline and radiolabeled antibodies anti-human IgG or IgM. Later, fetal calf serum or adult 
bovine serum or plasma were added to the buffer/diluent to increase the optical density 
readings of bound aCL and reduce unspecific binding, therefore increasing the specificity of 
the assay. Afterwards, anti-human IgG/IgM antibodies were enzyme-labelled instead of 
radio-labelled.  
In the ‘90s it was discovered that the reason why these diluents give a better signal is that 
they contain other antigens that, in turn, bind to cardiolipin-coated wells. Examples of these 
are plasma protein β2GPI, which binds to cardiolipin with high affinity, but also 
lipopolysaccharide binding protein (LBP), C4b-binding protein (C4BP), and thrombin-
modified antithrombin (AT)173, making it more and more evident that aPL are an 
heterogeneous group of antibodies that bind to different antigens.  
Enzyme-linked immunosorbent assays (ELISA) utilize cardiolipin or other anionic 
phospholipid in solid-phase, but most aPL need β2GPI in order to bind to cardiolipin
10. The 
reason why fluid-phase immunoassays are insensitive to aPL is because anti-β2GPI do not 
recognize the glycoprotein in its circular conformation. Instead, solid-phase are prepared 
using negatively charged plates that can bind human β2GPI.  
When β2GPI was discovered as the main antigen of aPL, solid-phase ELISA assays were 
developed to specifically detect anti-β2GPI. Some discrepancies unfortunately exist between 
different assays. Some examples are:  
 the type of plates 
 the concentration and orientation of the protein on the plates 
 the source of β2GPI and its purity: not all human anti-β2GPI bind to animal-derived 
β2GPI and antibodies against bovine proteins can be found in human blood 
At first, the results of the tests were given as “positive” or “negative”, without quantification. 
When it was noticed that patients with higher titers of antibodies, expressed as Optical 
Density Units (ODU), had a stronger association with thrombosis/obstetric complications, it 
became important to define also the level of positivity. Due to the high intra- and inter- 
laboratory variability, it was challenging but necessary to reach a standardization of the 
assays used for aCL testing16,18,174,175. In 2010, at the 13th International Congress on aPL, a 
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task force of researchers discussed critical questions related to standardization of aPL testing, 
providing international recommendations for pre-analytical (e.g. obtaining and preparing the 
samples), analytical and post-analytical issues18. Cut offs for aPL were established as the 99th 
percentile value of a reference population representative of the target population being tested. 
Between the 95th (mean ± 2SD) and 99th percentile (mean ± 3SD), results are considered 
indeterminate and should be repeated. For aCL, also >40GPL/MPL was established as cut-
off for positivity, considering that one GPL/MPL arbitrary unit is defined as the cardiolipin‐
binding activity of 1μg/ml of affinity‐purified IgG or IgM aCL. The coefficient of variation 
(CV) should be <10%, max 20%. The last guidelines were published in 2020168,169,176. 
Apart from repeating the tests after at least 12 weeks according to classification criteria, it is 
not known if and how often these tests should be repeated during the course of the disease, 
and not even if the risk of thrombosis decreases after negative results. An old prospective 
study by Out et al177 showed fluctuations in LA/aPL positivity in SLE patients, followed-up 
for a median of 26 months, mostly for IgG aCL (49%) and IgM aCL (30%), whereas LA was 
more stable (23%). These fluctuations were influenced partly by disease activity (especially 
for IgG aCL) and prednisone use (for LA). The PROMISSE study reported a modest 
decrease of aPL/LA during pregnancy that returns to baseline by 3 months post-partum178. A 
more recent prospective study on SLE shows that aCL tend to normalize in 40-50% of 
patients, depending on the isotype (more normalization for IgA and IgM than for IgG aCL), 
whereas this was true for LA in just 20%. Seventy-six percent of patients who became LA 
negative and 60% of those who had a normalization of IgG aCL, reacquired LA/IgG aCL 
within 5 years, in comparison with 37% and 17% in case of IgM and IgA aCL, 
respectively179.   
1.8 Thrombin Activatable Fibrinolysis inhibitor (TAFI) and fibrinolysis in APS 
1.8.1 Characteristics of the clot in APS 
Fibrin is the main component of the clot. It is a highly extensible fiber, that can be stretched 
up to 3.2-fold before breaking, and up to 4.3-fold when stabilized by cross-linking with 
fXIIIa. Clots are made of networks of polymerized fibrin monomers, which structure is 
characterized by different fibrin thickness, branching angles, quality and quantity of 
fibrinogen, pore size180. They are best visualized by Scanning Electron Microscopy (SEM). 
Both genetic (EuroCLOT study181) and environmental factors such as oxidative stress 
contribute to the characteristics of the clot, as well as local variables such as fibrinogen, 
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thrombin, fibrinolysis inhibitors concentration, the binding properties of tissue plasminogen 
activator (tPA) and plasminogen. 
The Darcy constant Ks and Clot lysis time (CLT) can be used to numerically quantify the 
permeability of the clot (see also section 3.2.1). When Ks is low and/or CLT is prolonged, it 
indicates a less permeable clot, tightly packed, composed by thinner, shorter and more 
numerous fibrin strands that are difficult to lyse. Conversely, when Ks is high and CLT short, it 
means that the clot is highly permeable, easy to lyse, composed by thicker fibers that may lead 
to bleeding. These parameters are usually inversely correlated with thrombin and fibrinogen 
concentration. 
For a description of the fibrinolytic process, see section 1.10.1. 
Alteration of fibrinolysis/fibrin structure associates with thrombosis in the general 
population182-185. The Darcy constant Ks has been shown to be reduced by 25% in acute 
thrombosis and advanced atherosclerosis, by 10-15% in subjects >65 years old and in obese 
patients (BMI > 35 kg/m2), by 15-20% in subjects with positive family history of 
thrombosis. It is increased by statins, antithrombotic agents and anticoagulants. Tighter fibrin 
clots, denser structures with decreased permeability and increased stiffness have been 
demonstrated in patients affected by venous thromboembolism (DVT186 and PE), arterial 
thromboembolism (MI and stroke187) and even metabolic syndrome. The metabolic 
syndrome is one of the main risk factor for CV diseases, defined by waist circumference >94 
cm in men or >80 cm in women plus any 2 of: triglyceride >1.7 mmol/L or specific 
treatment, HDL <1.03 mmol/L in men or <1.29 mmol/L in women or specific treatment, 
systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm Hg or specific 
treatment, fasting glucose >5.6 mmol/L or diabetes mellitus. It has been shown that clot 
permeability decreases proportional to the increasing presence of metabolic syndrome 
variables181.  
The clot properties of APS patients are different not only from healthy controls, but also 
from non-APS patients affected by thrombosis (figure 2). The fibrin network in APS clots is 
even more compact, less permeable and poorly lysable188,189. It contains more complement 
fragments C5-C9 (especially higher in triple positives and in LA+), immunoglobulins, 




Figure 2 – Scanning Electron Microscopy (SEM) illustrating the difference in clot structure 
between patients affected by APS and healthy controls 
 
1.8.2 TAFI  
TAFI is a carboxypeptidase B-like zymogen of 58kDa that downregulates fibrinolysis after 
activation. Its gene is located on chromosome 13q14 and spans 11 exons. It is produced mostly 
by hepatocytes, macrophages and megakaryocytes and it has a variable concentration in plasma, 
varying between 4 and 15 μg/ml191. Twenty-five percent of this variability can be explained by 
genetic polymorphisms, the rest by environmental factors192. TAFI can be measured in plasma 
with an antigenic method (sandwich ELISA) or by activity (functional) assay191. TAFI is mostly 
released in plasma as an acute-phase reactant. Its activated form, TAFIa, is a 35kDa highly 
unstable enzyme with a half-life of ca 8-10 minutes at 37°C, 2 hours at room temperature, 
whereas it is stable at 0°C. Because of this instability, it is challenging to measure191,193. TAFIa 
cleaves carboxyl-terminal lysine and arginine residues from partially degraded fibrin, limiting 
tPA and plasminogen binding and subsequent plasmin generation, also promoting the inhibition 
of plasmin by α2-antiplasmin. TAFI is activated during coagulation, with the aim of protecting 
and stabilizing the newly formed clot. It has been shown in vitro to be triggered by trypsin, 
plasmin and thrombin, and enhanced by 1250-fold by the thrombin-thrombomodulin complex 
(IIa-TM)192. Thrombomodulin (TM) is an integral membrane glycoprotein made of 557 amino 
acids organized in five distinct domains, with a molecular weight of 70-100kDa, mainly 
expressed on the luminal surface of endothelial cells, but it is also found in circulation as a 
shorter soluble variant. Its plasma concentration is ca 10ng/ml and it increases in conditions of 
endothelial dysfunction/activation, e.g. during Acute Respiratory Distress Syndrome (ARDS), 
DIC, hypertension194 or in case of liver or renal failure195. TM has also anticoagulant properties: 
it inhibits thrombin’s pro-coagulant functions and works as a cofactor for thrombin in the 
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activation of anticoagulant protein C. Thrombin has both pro-coagulant and anti-coagulant 
functions depending on its concentration, the so called “thrombin paradox”: anticoagulant at 
lower concentrations, pro-coagulant at higher concentrations. Also the complex thrombin-TM 
has a dual function on fibrinolysis: anti-fibrinolytic at low TM concentrations, pro-fibrinolytic 
at higher TM concentrations. This phenomenon has been called the “TM paradox” (figure 3). It 
was shown by observing a prolonged clot lysis time (CLT) at lower TM concentration that was 
reduced with increasing TM concentrations. The reduction of the CLT was less pronounced 
after the addition of a protein C or protein S inhibitor196. The explanation is that the complex 
thrombin-TM activates protein C at higher TM concentrations in vitro in normal plasma (ca 
10nM), whereas the same complex preferentially activates TAFI at low TM concentration (ca 
1nM). In fact, activated PC (APC) inhibits TAFI activation through the downregulation of 
thrombin generation in a sort of negative feedback loop. Together with protein S, APC 
inactivates fVa and fVIIIa that are needed for thrombin activation. To confirm these findings, 
Mosnier et al196 used also plasma from a patient homozygous for factor VLeiden, showing that, in 
this case, the activation of TAFI is not decreased for increasing TM concentrations, as expected. 
In fact, since the mutated fVa is resistant to APC cleavage (see also section 1.10.5), the activity 
of the prothrombinase complex is unopposed, leading to increased thrombin generation, able to 
activate more TAFIa for increasing TM concentrations. They also demonstrated the same 
properties of TM on cultured human microvascular endothelial cells. Vessel size and location 
are also determinants of local TM expression on endothelial cells. Small arteries such as those 
in the brain or in the coronary circulation have lower concentrations of TM compared with 
veins. Thus, in the vessels where TM concentration is lower, high levels of TAFI may 
downregulate fibrinolysis and reduce the capacity to remove fibrin clots. Other factors are 
involved in the regulation of TAFI activation and can steer the balance more towards TAFI or 
protein C activation independently from TM concentration. For example, protein C inhibitor 
(PCI) and coagulation factors fXa and fXIa tend to limit protein C activation even at higher TM 
concentration, shifting the curve towards more activation of TAFI, whereas others, such as 
protein S, endothelial protein C receptor (EPCR) or platelet factor-4 (PF4), activate less TAFI at 




Figure 3 – The thrombomodulin (TM) paradox 
The black curve indicates pro- and anti-fibrinolytic effects mediated by TM, depending on its 
concentration. Stimulation of TAFI activation by low concentrations of TM is responsible for 
anti-fibrinolytic effects (red color), whereas stimulation of protein C activation at higher 
concentrations of TM is responsible for pro-fibrinolytic effects (light blue color). Cofactors that 
stimulate protein C activation, APC anticoagulant and pro-fibrinolytic activity are illustrated in 
light blue (curve shifts to the left), whereas those that enhance TAFI activation and its anti-












Apart from its anti-fibrinolytic properties, TAFIa is also anti-inflammatory because it 
inactivates, via cleavage of the COOH-terminal arginine residues, the two most powerful 
anaphylatoxins derived from complement activation, C3a and C5a, as well as bradykinin (a 
vasodilator) and osteopontin (promoter of chemotaxis)192,193,197-201. Also TM has anti-
complement properties by enhancing factor I degradation of C3b114,201,202,1. 
TAFI has been studied in relation to venous203-205 and arterial206-210 thrombosis, as well as in 
SLE211, RA212 and Behcet disease213-215, with controversial results. The most relevant studies 













474 first DVT, 




474 age and sex-
matched healthy 
Increase of TAFI with age 
in healthy women. TAFI 
>90th percentile in 14% 
DVT vs 9% controls, but 
same mean. OR of DVT 
1.7 (95%CI 1.1-2.5) TAFI 
> vs < 90th. Impact of 





114 ischemic stroke 
(IS) < 80 years old, 
mean age 56, 45% 
women 
150 age and sex-
matched healthy, 
55% women 
Higher in IS vs controls 
(113.7% vs 102.6%, p 
<.05). Adjusted OR 5.7 
(95%CI 2.3-14.1) for IS 
when TAFIa >120%. No 
difference in LA and aCL 
between groups. No 
correlation between TAFIa 
and CV risk factors, which 
were all more prevalent in 




600 first spontaneous 
VTE prospectively 
(mean follow-up 45 






High TAFI (>75th 
percentile) correlated with 
recurrence 2 years after 
anticoagulation (14.5% 
recurrence with high TAFI 





TAFI (ELISA), CRP 
105 Behcet disease 
(BD), 61% men, mean 
age 36, all negative 
aPL 
53 age and sex 
matched 
healthy 
Higher in BD vs controls 
(91.1 vs 14.3, p<.001), no 
difference in subgroups 
with/without thrombosis. 
No correlation between 







67 SLE, 15% men, 
mean age 40, 27% 
(18/67) past 
thrombosis: 9/18 
(50%) arterial, 5/18 
(28%) venous, 4/18 
(22%) both. 







Not significantly higher in 
SLE vs controls (75.7 vs 
66.9, p=0.07), no 








TAFI (antigenic method), 
TAFIa (chromogenic 




I, 32/72 β-blocker. All 
non-smokers 
- 
TAFI weakly correlated 
with diastolic BP in 
untreated patients (r=0.27) 
and patients on β-blocker 
(r=0.25), with systolic BP 





TAFI (ELISA), TAFIa 
(STA-Stachrom TAFI) 
79 BD: 22/79 previous 
VTE, 3/79 stroke and 
angina. Samples 
collected >6 months 
after thrombosis 
84 healthy 
TAFI (p=.013) and TAFIa 
(p<.001) higher in BD vs 
controls. BD have higher 
CV risk factors. TAFIa 
remains higher after 
adjustment. TAFIa higher 







1668 CAD mean 
follow-up 2.3 yrs. 
56/1668 CV deaths 
and 35/1668 non-fatal 
CV events. Nobody on 
anticoagulants 
- 
TAFIa/TAFIai HR for CV 
death 1.69 (95%CI 1.07-
2.67) adjusted for 
traditional CV risk factors, 
CRP, markers of thrombin 
generation and fibrinolysis 
De Bruijne, J 
Thromb Haemost. 
2009206 
TAFI, TAFIa, TAFIai (in 
house ELISA + functional 
assay) 
327 patients: 218/327 
first CHD, 109/327 
IS/TIA, 46% men, 
mean age 43 years  
322 healthy 
TAFIai higher vs controls 
(145.1 vs 137.5, p=.02). 
TAFI higher in CHD vs 






554 first MI men 
< 70yrs, mean age 56 
643 healthy, 
mean age 57 
Lowest quartile of TAFIa 
associated with first MI 
(OR 2.8, 95%CI 1.9-4.0; 
adjusted OR 3.4, 95%CI 
2.3-5.1). Positive 










21 RA with CRP 
>10mg/L, 33% men, 
mean age 63 





Higher (147% vs 114%, 
p<.01) in active RA, non-
significant difference after 




TAFIa (chromogenic, in 
house), PAI-1, 
plasminogen 
770 first DVT (62%), 
first PE (28%), or 
both (10%), enrolled 








age, sex and 
geographical 
area 
PAI-1 and TAFIa 
positively associated with 
CLT and VTE, 
plasminogen inversely 
associated with CLT. 





TAFIa (ELISA), TM 
89 BD, 50% men, 




mean age 38 
TAFIa lower in BD (13.5 
vs 26.8), TM higher (3.2 
vs 2.6). No difference of 
both TAFIa and TM 
according to VTE. 
Positively correlated 
TAFIa-TM in healthy 






1.8.3 TAFI in APS 
TAFI antigen has been studied in relation to aPL/LA first in 2007 in LA positive patients 
affected by SLE211 (see table 1), and no difference in antigen levels were found according to 
LA positivity or previous thrombosis.  
The studies on TAFI specifically in APS are presented in table 2, and they were mainly in 
relation to pregnancy, obstetric complications and CLT216-218. The only previous study that 
measured also the activated form of TAFI (TAFIa) in non-pregnant APS patients, classified 
according to Sapporo criteria, was performed in Japan, by Ieko et al219 in 2010. They noticed 
that APS patients have higher levels of both TAFI and TAFIa compared to healthy controls, 
but lower than patients with other autoimmune diseases (including SLE, rheumatoid arthritis, 
Sjögren, Systemic Sclerosis), and no APS. There was no difference between pAPS and sAPS 
in both TAFI and TAFIa levels, but after comparing SLE patients with sAPS vs non sAPS, 
TAFIa was higher in the second group. TAFIa was lower in aPS/PT+ and LA+, as compared 
to negative. They also showed that purified monoclonal IgG aPL inversely correlate with 
TAFIa in vitro, in a concentration dependent manner. The authors suggested that aPL may 
affect the thrombin-TM complex by binding to phospholipid-binding proteins, in particular 
β2GPI that has been shown to inhibit protein C activation in vitro
220. In this way, although 
lacking definitive proof of a causal relationship, aPL could steer the thrombin-TM action 
away from TAFI activation. Nevertheless, previous research has demonstrated the inhibitory 




Table 2 - TAFI in APS 
Author, Journal, 
Year 
What Patients Controls Findings 
Martinez-Zamora, 




67 pregnant pAPS 
(Miyakis) 
66 pregnant non APS 
Prolonged baseline CLT in 
APS vs controls. No difference 
in CLT or TAFI for 
thrombosis/obstetrical 
outcome. Progressive increase 
of TAFI and CLT in 
pregnancy, normalizing after 
delivery 
Ieko, International 






68 APS (Sapporo 
criteria), mean age 46, 
90% women: 27/68 
pAPS, 41/68 sAPS, 
39/41 SLE sAPS 
66 healthy, mean age 
46, 62% women, 46 
other autoimmune 
diseases (AI), mean 
age 42, 83% women, 
27/46 SLE non sAPS 
(2/27 aCL+) 
TAFI higher in APS vs 
controls (p<.001), higher in AI 
vs APS (p=.024) and controls 
(p<.001), no difference in 
pAPS vs sAPS. TAFIa higher 
in APS and AI vs controls 
(p<.001 for both), higher in AI 
vs APS (p>.001), higher in AI 
vs sAPS (p<.001), no 
difference in pAPS vs sAPS. 
TAFIa higher in SLE non 
sAPS vs SLE sAPS, TAFI 
same. TAFIa lower in LA+ 
and aPS/PT+, same TAFI. 
Purified monoclonal IgG aPL 








82 pregnant with severe 
pre-eclampsia (PE), 10 
APS with pre-eclampsia 
76 APS pregnant, 
89 healthy pregnant 
CLT > in PE, APS-PE and 
APS vs controls, longer in PE 
ad APS-PE vs APS. 
TAFI higher in PE and APS-
PE vs APS and controls 
Martinez-Zamora, 
Fertility and Sterility 
2010216 
TAFI (ELISA) 
63 APS previous >3 
spontaneous abortions 
<10th week, mean age 
33 
119 non APS previous 
>3 spontaneous 
abortions <10th week; 
64 age matched 
healthy 
TAFI higher in abortion non 
APS, CLT prolonged in APS 





1.9 Myocardial Infarction in APS 
Myocardial Infarction (MI) is not one of the most common manifestations in APS. In the 
Euro-Phospholipid project study22-25 it was the presenting clinical feature in 2.8% of patients, 
with a cumulative frequency of 5.5% registered from symptom onset until enrollment and 
1.9% was the reported incidence during 10 years follow up. In the retrospective, population-
based study of Duarte-Garcia, no MI were registered19. Taking it from another perspective, 
in patients affected by MI, the prevalence of aPL/LA has been estimated to be around 11%, 
as outlined before55.  
1.9.1 Traditional cardiovascular risk factors 
Traditional cardiovascular (CV) risk factors should be considered in the evaluation of APS 
patients, especially regarding the risk of arterial events223,224. 
The SCORE risk estimation system was created in 2003 by the European Society of 
Cardiology (ESC) in order to estimate the risk of a fatal MI within 10 years through charts 
easily applicable in the clinical practice223. The need for new scoring systems derived by the 
fact that the only available risk estimator until that time was calculated from the Framingham 
cohort224 and it became clear that it was not correctly applicable to the European population, 
because of a lower incidence of coronary heart disease as compared to the United States. The 
SCORE system estimates the total burden of CV risk of an individual, considering the 
interaction between total cholesterol (or total cholesterol/HDL ratio), age, sex, smoking 
status and systolic blood pressure. The charts are differentiated in low and high risk 
European countries, based on the baseline cause-specific mortality. The estimation doesn’t 
include non-fatal CV events, because their definition is not unanimous across different 
studies and the availability of data is restricted. Diabetes is not included in the chart because 
of lack of unanimous data, but men with diabetes have approximately a two-fold and women 
a four-fold risk compared to that given by the charts. Diabetes-related factors, such as type 
and duration of diabetes, glycemic control, presence of retinopathy, microalbuminuria and 
proteinuria are considered in separate, specific CV risk calculations tailored for diabetic 
patients. Similarly, patients with inflammatory joint disorders are considered to have a higher 
CV risk than the general population, similar to, or even higher, than diabetes225. In order to 
take this into account, the more recent EULAR recommendations advocate the inclusion of a 
multiplication factor of 1.5 in the CV risk prediction models for all patients affected by 
rheumatoid arthritis. In the overarching principles of the same document, the authors also 
state that the higher CV risk may also apply to other inflammatory joint diseases226. 
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Also patients affected by APS are at increased risk of thromboembolism compared to the 
general population. The Global Anti-Phospholipid Syndrome Score (GAPSS)227 is an 
attempt to take into consideration some clinical and laboratory APS-related factors that are 
believed to increase the risk of thrombosis in any vessel or pregnancy complications. The 
variables included in the score are a combination of some conventional CV risk factors 
(hyperlipidaemia and hypertension), together with criteria and non-criteria aPL (IgG/IgM 
aCL, IgG/IgM anti-β2GPI, LA and IgG/IgM aPS/PT)
228,229. It remains to be assessed whether 
novel biomarkers, such as anti-domain I β2GPI, could further refine APS risk prediction. 
1.9.2 Atherosclerosis and Autoimmunity  
Atherosclerosis is the main cause of coronary arteries occlusions and carotid artery 
thromboembolism, leading to myocardial infarction and stroke, respectively. Subclinical 
inflammation and endothelial dysfunction are involved in its pathogenesis. Many studies 
over the recent years have hypothesized a link between autoantibodies and autoimmune-
mediated accelerated atherosclerosis230,231, in particular IgG anti-oxLDL/β2GPI
232-237. 
Oxidized LDL (OxLDL) are low density lipoproteins that have been oxidized in their lipid 
and apo-B components by lipid peroxidation. This process is believed to take place mostly in 
the subendothelium and it represents one of the earliest pro-atherogenic events. It has been 
demonstrated that β2GPI is abundantly present within the atherosclerotic lesions, both intra- 
and extracellularly. In the intima, OxLDL form a complex with β2GPI, which constitute a 
target for anti-oxLDL/β2GPI
238. IgG anti-oxLDL/β2GPI have been shown to enhance the 
uptake of oxLDL by macrophages via scavenger receptors239 and to promote the formation 
of macrophage-derived foam cells237 and the development of fatty streaks in the arterial wall. 
Macrophages then produce matrix-degrading proteases and TF that eventually lead to plaque 
rupture and thrombus formation240. IgG anti-oxLDL/β2GPI have been found in the 
circulation of patients with APS/SLE241 and some studies have shown a positive correlation 
with arterial thrombosis242.   
1.9.3 aPL/LA in patients with Ischemic Heart Disease 
The literature on Myocardial Infarction (MI) and positivity for aPL/LA is large and 
controversial (table 3), due to limited sample size, selected populations and/or non-
standardized/old methods/variable cut offs for antibody determination. Therefore it is not 
easy to compare different studies and give a unanimous answer to the question of the 
association between aPL/LA and Ischemic Heart Disease. 
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In 1986 the pioneer study of Hamsten et al243 observed an increased prevalence of patients 
with elevated aCL titers in a highly selected series of young patients after a MI. Furthermore, 
high titers of these antibodies correlated with recurrent venous or arterial thrombosis during 
36-64 months of follow-up. No difference was reported between aCL+ and aCL- patients 
regarding CV risk factors or angiographic findings. In the following years, other studies 
demonstrated associations between aCL and ischemic heart disease/MI, whereas in others 
the frequency of elevated aCL antibodies was not particularly higher in patients than in 
control subjects. The majority of the studies did not report a prognostic role for aPL on 
subsequent cardiovascular complications244-254, though some did242,255,256. Many studies were 
performed on survivors of MI or in patients with established coronary heart disease (CHD), 
sometimes measuring aPL very close to the time of the event. Others, like Vaarala et al253 
and Wu et al242, were able to investigate the association between aCL and the risk of MI 
prospectively and longitudinally, collecting samples in initially healthy subjects in the 
context of primary prevention studies, with long follow-ups. Some studies, like Meroni et 
al257, focused on particular antigenic specificities of aPL (anti-β2GPI) in a highly selected 
population (premenopausal women). Others, like Davies and Hunt258, focused their research 
on young adults hit by a first MI with normal coronary angiograms and no signs of 
atherosclerosis. They showed an unexpectedly high prevalence of LA positivity, which 
steered treatment towards anticoagulation, which turned out to be efficacious in terms of lack 
of recurrences during follow-up. Also Urbanus et al259, in a case-control study, found a 
significant difference in LA positivity between MI patients and healthy subjects, but not in 




Table 3 – MI and APS/aPL 
Author, Journal, 
Year 
What Patients Controls When Findings 
Hamsten, The Lancet 
1986243 
aCL IgG (Harris cut 
offs 5 GPL) 
62 MI, 90% men, < 45 
years, mean age 41 years 
- 
3, 12, 36 months 
post MI 
21% (13/62) positives in 2 occasions 
11% (7/62) positives in all three 
occasions. No difference in risk 
factors and angiographic findings. 
61% (8/13) in aCL+ re-thrombosis vs 
25% (12/49) in aCL- at 36-64 months 
follow-up 
Morton, The Lancet 
1986256 
aCL IgG, IgM 
83 CABG < 70 years 
old, 83% men, mean age 
55, LDA/placebo.  
55% (46/83) had prior 
MI 
- 






Association between preoperative 
aCL, occlusions and number of 
occluded anastomosis. No difference 
in preoperative aCL+ between prior 
MI or not. Occlusion rate showed a 
trend: the higher aCL titers, the more 
occlusions. Postoperative aCL+ 
higher in prior MI vs not. 20% 
(17/83) aCL+ preoperative, 82% 
(68/83) raised aCL in 12 months 
follow-up 
Klemp, Clin exp 
Immunol 1988248 
aCL IgG, IgM 
86 IHD, 63% men, mean 
age 61: 21% non ECG 
changes, 38% ECG 
changes, 41% MI 
124 healthy mean 
age 31, 62 RA 
mean age 49, 20 
tuberculosis mean 
age 31 
1-5 days after 
admission 
Higher aCL in IHD vs other groups. 
No differences within IHD, no 
association with complications 





40 MI, all males < 50 
years old, mean age 45 
41 general 
population mean 
age 39 and 30 
chronic CHD 




after 4 weeks, 3 
months (patients 
only) 
18% higher increase in IgG, 26% 
IgA, 43% IgM between 0 and 4 
weeks compared to controls. Slightly 
decreased at 3 months 
De Caterina, Am J 
Cardiology 1989245 
aCL IgG and IgM, cut 
off 10 U 
119 chest pain: 75/119 
stable CAD, 29/119 
unstable CAD, 15/119 
non ischemic chest pain 
(mean age and 
male/female non 
reported) 
83 healthy, 72% 
men 
At recruitment 
IgG aCL >1U in 42% (50/119) vs 
53% (43/83) in controls and 43% 
(45/104) in CAD. Titers: 2.67 vs 2.62 
and 2.74 CAD. IgM >1U in 5%. 
Never >10U!  
No association with recurrences at 2 





aCL IgG and IgM, cut 
offs 6 MPL, 10 GPL 
74 men, mean age 60, 
chest pain: 16/74 CAD 
mean age 67, 34/74 
CAD + prior MI mean 
age 59, 14/74 MI mean 
age 61, 10/74 without 




No differences between the groups, 
no association with 
severity/chronicity of CAD 
Sletnes, Thromb 
Research 1990251 
aCL 97.5th percentile, 
anticephalin 
49 MI, 71% men, 
median age 67 years. 
28% (14/49) had 




after 1 week, 6 
weeks, 9 months 
6% (3/49) aCL+, 16% anticephalin+ 
constant in the 4 measurements apart 
from 4% (2/49) that became IgG + > 
6 weeks 
Sletnes, The Lancet 
1992252 
aCL IgG and IgM, cut 
off 97.5th percentile, 5 
GPL, 3.6 MPL, 
anticephalin 
597 MI <75 years, 70% 
men, mean age 62,  
1983-86 warfarin 
158 healthy and 
with cataract, 
mean age 47 years 
6-180 days post 
MI, mean 28 days 
6% (37/594) vs 4% controls (ns) 
aCL+, 13% anticephalin+ MI vs 4% 
controls. After adjustment for 
traditional CV risk factors, no 
association with mortality or 
recurrence at 3 years follow-up 
Cortellaro, The 
Lancet 1992244 
IgG aCL and LA 
62 MI < 45 years old 
(mean age and 
male/female non 
reported) 
- 3 months after MI 
13% (8/62) aPL+. No association 
with complications at 24 months 
follow-up 
Phadke, Br heart J 
1993249 
aCL IgG and IgM. 
Cut offs 5 GPL, 3 
MPL, low 5-15, 3-6, 
respectively 
307 MI < 60 years old, 
80% men, median age 
53, and 160 unstable 
angina, 62% men, 
median age 52 
Age and sex 
matched healthy 
Day 1 and 5, 5 
weeks, 5 months, 
12 months after 
No difference and no association with 
complications at follow-up 
Raghavan, J Clin 
Pathol 1993250 
aCL IgG cut off 10 
GPL, IgM cut off 5 
MPL (ELISA) 
111 suspected MI, 75% 
men. Confirmed MI in 
83/111 patients, median 
age 61 years: 16% with 
previous MI, 36% 
previous angina.  
28/111 IHD and 
unstable angina, 
median age 63: 
57% with previous 
MI, 75% previous 
angina 
On admission, 
after 24h, 5-7 
days,  6-8 weeks 
18% (20/111) aCL+, 60% male, 
older.  
8% (9/111) aCL+ consistently: 2/9 
IgM+, 7/9 IgG+. No differences 
between MI and IHD, between prior 
MI or not, no association with 
complications 
Edwards, The Lancet 
1993261 
aCL IgG and IgM cut 
off 25 GPL/MPL 
249: 159/249 MI, 87% 
men, mean age 58 years, 
90/249 unstable angina, 
71% men, mean age 56 
years 
299 healthy, 50% 
men, mean age 47 
years 
At admission No difference. No aCL + < 45 years  
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Yilmaz, Clin Cardiol 
1994254 
aCL IgG and IgM 
(ELISA), cut offs 6 
MPL, 11 GPL 
76 CHD, 85% men, 
mean age 42: 32 MI, 22 
CHD and prior MI, 22 
CHD 
22 healthy, 54% 
men, mean age 27 
3, 14, 90 days 
after MI, the other 
groups just once 
47% (36/76) IgG aCL+, 12 GPL vs 7 
GPL in controls (low levels). No 
difference in IgM. No correlation 
with age, risk factors, morbidity, 
mortality, severity, complications at 




absorbance cut off  
(solid-phase ELISA) 
22 unstable angina, 
95.5% males, mean age 
60, 27.3% MI 
- < 48h 
36.4% (8/22) aCL+, <50 years more 
aCL+. No differences in CV risk 
factors, severity of disease, 
recurrences, outcome, complexity, 
thrombus localizations 








102 MI, 78% men 
102 healthy, 10 
APS 
< 4h and after 3 
months 
aPL higher in <50 years old vs >50. 
At least one aPL high in 7% of MI, 
6% aCL+, all men <50. Normalized 
at 3 months. No association with 
traditional CV risk factors. 
Vaarala, Circulation 
1995253 




133 MI (107 non-fatal 
MI, 26 cardiac deaths) 






At entry in the 
cohort (1981-82), 
max 5 years 
before MI 
The highest quartile of aCL titers had 
an adjusted OR for MI of 2.0 (95% 
CI 1.1-3.5). aCL correlated to anti-
oxLDL (r=0.40). No association with 
mortality. IgG aCL 0.41 optical 
density units (ODU) in MI vs 0.36 
ODU in controls, higher in smokers 
Zuckerman, Am J 
Med 1996263 
aCL IgG and IgM, cut 
offs 10 GPL and 8 
MPL 
124 MI < 65yrs, 72.5% 
men, mean age 55 
76 chest pain, 76% 
men, 62% IHD, 
16% prior MI, 
6.5% prior 
thrombosis, 
matched for age 
and CV risk 
factors 
Admission < 24h,  
3 months 
14% (17/124) aCL+ vs 3% (2/76) in 
controls, IgG in 9.6%, remained in all 
but 1 after 3 months. Higher rate of 
thrombosis and re-MI at 19 months 
follow-up in aCL+ vs aCL- (41% vs 




aCL IgG, IgA, IgM 
Healthy < 50 years men. 
119 developed MI 
between 50-70 years 
old: 80/119 non-fatal, 
39/119 fatal 





Follow-up for 20 
years 
Raised aCL IgG and IgA correlated 
with incidence of MI and MI-related 
mortality 10-20 years later. Adjusted 
OR aCL IgG 1.49 (95%CI 1.11-1.99), 
IgA 1.48 (95%CI 1.06-2.06).  More 
CV risk factors in MI vs non-MI. 
Trend higher titers in fatal MI - 





aCL and anti-β2GPI 
IgG, IgM (ELISA). 
Cut offs 23 GPL 
(=23μg/ml) and 11 
MPL for aCL, 20 
SGU and SMU for 
anti-β2GPI 
1150 MI, 75% men, 
48% > 60 years old, 




10.9 days after MI 
Higher aCL IgG (HR 1.63 adjusted, 
Cox, p=0.01) and lower aCL IgM 
(HR 1.76 adjusted, p=0.02) 
independent risk for recurrent cardiac 
events (fatal or not, n=131) at mean 
24.6 months follow-up. Higher 
recurrences in high IgG aCL and low 
IgM aCL (p<0.001). Dichotomized in 
quartiles, higher >12.5GPL, 
>4.1MPL! r=0.50, p<0.005 between 
IgM aCL and IgM anti-β2GPI 
Dropinski, Med 
Sci Monit 2003264 
aCL IgG, IgM, cut 
offs 10 GPL and 20 
MPL 
50 male <50 years old 
survivors of MI, mean 
age 45 
50 healthy, mean 
age 44 
> 6 months 
24% (12/50) aCL+ in MI survivors vs 
6% (3/50) in controls, crude: all other 
traditional CV risk factors differed 
between groups. 
Mean IgG 9.2 vs 7.7, IgM 18.5 vs 




aCL and anti-β2GPI 
IgG, IgA, IgM and 
LA. Cut offs 22 GPL, 
16 MPL for aCL, 15 
SGU, 43 SAU, 34 
SMU for  anti-β2GPI 
111 ACS, 59% men, 
mean age 59: 38/111 
Unstable Angina (UA), 
26/111 NSTEMI, 
47/111 STEMI 
50 healthy, 60% 
men 
At hospitalization 
14% anti-β2GPI + in ACS (18% in 
men, 8% in women: ns difference, 
higher %  in <50 years old and in 
those who died) vs 2% in controls. 
Higher titers IgA anti-β2GPI in ACS. 
No difference in aCL. Nobody was 
LA+. IgA anti-β2GPI associated with 
previous stroke, not with 
hypertension or previous MI, and 
higher concentration in UA and 
STEMI, not NSTEMI. IgG and IgM  
anti-β2GPI correlate with IgG and 
IgM aCL 
Meroni, J Thromb 
& Hemostasis 
2007257 
aCL and anti-β2GPI 
IgG, IgM, 
ANA. 
Cut off 10 GPL and 
MPL for aCL, > 99th 
percentile for anti-
β2GPI  (>0.13 IgG, 
>0.28 IgM) 
172 first MI 
premenopausal women 
< 45 years old, mean age 
39: 62% significant 
stenosis, 16% non-
significant, 22% no 
stenosis.  
50 unselected MI, 86% 
men, mean age 53 
172 matched for 
age, sex and 
geographical 
origin 
3-12 months after 
(for unselected MI 
within 3 weeks) 
anti-β2GPI IgG: 9 vs 2% 
anti-β2GPI IgM: 11 vs 3% 
OR adjusted for hypertension and 
smoking IgG 2.47, IgM 3.68 for the 
fourth quartile, cut off 13.9%. 





1.10 Complement, complement regulators and anticoagulants in APS  
1.10.1 Interaction between coagulation, fibrinolysis and complement 
Coagulation, fibrinolysis and complement cascades derive from a single common ancestral 
pathway, composed of serine proteases and SERPINs. Serine proteases are enzymes that 
cleave peptide bonds at a specific site in order to activate their substrates. On the contrary, 
SERPINs are serine protease inhibitors. These systems are tightly regulated, and they cross-
interact. 
The coagulation cascade183 (figure 4) starts in response to vascular injury, when platelets 
adhere, aggregate and expose the phospholipids necessary for the binding of clotting 
enzymes. There are two pathways of activation: the intrinsic (fXII) and extrinsic (fVII-TF) 
pathways, which join into the common pathway at fXa. The cascade ends with the formation 
of cross-linked fibrin, stabilized by fXIIIa through the binding with α2-antiplasmin. Positive 
and negative feedback loops regulate coagulation along the pathway. There are three main 
inhibitory mechanisms. The first is antithrombin (AT), a SERPIN that forms a complex with 
thrombin (TAT) and inhibits its actions. AT is potentiated by the help of natural heparin 
sulfate proteoglycans produced by the endothelium. The second is made of Activated Protein 
C (APC), helped by the cofactor PS, to inactivate fVIIIa and fVa, making them unavailable 
for fXa and thrombin formation, respectively. The third is Tissue Factor Pathway Inhibitor 
Davies, Int J Clin 
Practice 2007258 
Cases report (n=5) 
Various tests repeated 
+ 
5 MI < 50 years old 
with normal coronary 
arteries, 80% men, mean 
age 35 
- various All LA+ 
Urbanus, Lancet 
Neurology 2009259 
LA, aCL IgG, anti-
β2GPI IgG, aPT IgG 
203 first MI women < 








3% LA+ in MI vs 0.7% in controls, 
OR of MI 5.3 in LA+ vs 2.3 in LA-, 
21.6 if also Oral Contraceptives, 34 
LA+ smoke. No interaction tested. 
aCL and β2GPI non-significant. High 
cut offs for traditional CV risk factors 
Grosso, Ann Int 
Med 2018266,267 
aCL IgG, IgM, IgA,  
anti-β2GPI IgG, IgM, 
IgA. Cut-offs 10 GPL, 
30 MPL, 20 APL 
805 first MI <75 years 
old, 81% men, mean age 
62, from 17 Swedish 
hospitals, 2010-2014 
805 individual 
matched for sex, 
age, geography 
6-10 weeks 
11% IgG aCL and anti-β2GPI + in MI 
vs controls, OR 13, 7.8 adjusted. No 
difference in type/severity of MI 
between MI aPL+ vs aPL-. IgG aPL+ 




(TFPI) that inhibits the extrinsic pathway at the level of TF-fVII catalytic complex. Its 
functions are enhanced by heparin and protein S.  
Figure 4 – The coagulation system and natural anticoagulants 
In blue the intrinsic pathway of coagulation activation, in green the extrinsic pathway, in red 













Fibrinolysis (figure 5) has the goal of breaking down the clot, in order to preserve blood 
flow. The central enzyme of this cascade is plasmin, which main function is to disintegrate 
fibrin. Plasmin derives from the conversion of plasminogen, a circulating pro-enzyme, by the 
action of tissue (t) and urokinase-type (u) Plasminogen Activator (PA). u-PA binds to a 
specific cellular receptor (u-PAR, CD87), expressed by monocytes/macrophages, T cells, 
neutrophils, endothelial cells, epithelial cells (especially renal), smooth muscle cells, and 
fibroblasts, whereas t-PA is mainly synthesized by endothelium, neurons, microglial cells, 
and smooth muscle cells93. tPA concentrations in plasma are usually low, but they increase 
during stress and physical exercise. The binding of t-PA to fibrin considerably increases its 
affinity for plasminogen by 1000 to 1500-fold, further enhanced by annexin II, which also 
protect plasmin from inhibition268. The main inhibitors of the fibrinolytic pathway are 
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Plasminogen Activator Inhibitor (PAI)-1 and -2, Thrombin Activatable Fibrinolysis Inhibitor 
(TAFIa), α2-antiplasmin, α2-macroglobulin. 
 
Figure 5 – The fibrinolytic system and its main inhibitors 
In light blue the fibrinolytic pathway, in red the final pathway of the coagulation cascade. 










The complement system (figure 6) was discovered more than 100 years ago269. It is part of 
the innate immune system and its functions are to protect the organism from infectious 
agents and to recognize and remove modified self-cells. It also represents one of the effector 
arms of antibody-mediated immunity. The complement cascade can be divided into four 
main steps: initiation, C3 convertase and C5 convertase activation and amplification, and 
terminal complex formation. The initiation phase starts with the activation of any or all of 
three different pathways, depending on the substrate that is recognized: lectin (by 
carbohydrates on microbial surfaces and on apoptotic/necrotic cells), classical (mostly, but 
not only, by antigen-antibody complexes) and alternative (by spontaneous activation of C3). 
The more than 35 small components of the complement system are zymogens that circulate 
inactive, until they are enzymatically modified to, in turn, activate other substrates by 
proteolytic cleavage, in a cascade manner. In this way, the complement system can be 
activated only when and where needed. These reactions can be amplified in order to generate 
a potent inflammatory response when required, in particular with the formation of the 
anaphylatoxins C3a and C5a. 
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Figure 6 – The complement system and its main inhibitors 
In blue the classical pathway of complement activation, in pink the lectin pathway, in green 
the alternative pathway, in red the common pathway. Natural complement regulators are 













There are several examples of molecular interactions between the coagulation, fibrinolysis 
and complement cascades106,270-273 (figure 7). 
Complement can activate the coagulation cascade, for example the Terminal Complement 
Complex (TCC) is able to catalyze the cleavage of prothrombin to thrombin even without 
fVa. Mannose-associated serine protease 2 (MASP-2), a component of the lectin pathway, 
can activate thrombin. C5a upregulates Plasminogen activator inhibitor-1 (PAI-1) and 
induces TF on endothelial cells and neutrophils274,275, thereby contributing to the activation 
of the extrinsic coagulation pathway.  
On the other hand, coagulation/fibrinolysis proteases have been shown to cleave C3 and C5 
into the anaphylatoxins C3a, C5a in vitro and ex vivo. FXa is considered the most potent 
factor to mediate this proteolytic activation, but also thrombin, which can generate C5a even 
in the absence of C3276, plasmin, fIXa and fXIa272. In vitro, inhibition of fXa by 
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fondaparinux or enoxaparin reduces also fXa-mediated C3 cleavage, in a concentration-
dependent manner272. TAFI, generated by thrombin-TM complex, inhibits fibrinolysis and 
inactivates C3a and C5a. FXIIa can activate C1r.  
Other mechanisms apart from complement cleavage can explain the pro-inflammatory 
properties of some coagulation factors. For example, TF has been shown to play a role in 
pregnancy morbidity, but more through enhanced inflammation than coagulation. In an 
experimental study, Girardi et al275 could demonstrate that TF causes trophoblast injury, 
placental dysfunction and damage to the developing placenta and embryo by enhancing 
neutrophil activity. In fact, fibrin depositions and thrombi were not present after IgG aPL 
injection in pregnant mice, despite abundant TF staining throughout the decidua and on 
embryonic debris. 
Figure 7 – some interactions between the pathways 
The extrinsic pathway of coagulation and the alternative complement pathway are illustrated 
in green, in blue the intrinsic coagulation pathway and the classical complement pathway, in 
pink the lectin complement activation pathway, in red the common pathways of both 





It is intuitive that, if these cascades are so tightly linked and can influence each other, using 
treatments that target one pathway can have effect on another (more on this in 1.10.6). A 
further evidence of these tight interactions is given by the fact that anticoagulated plasma has 
lower levels of complement activation products than serum277, because coagulation factors 
activate complement. That’s the reason why EDTA plasma is used in complement 
measurement, because it is more efficient than citrate or heparin in blocking complement 
activation in vitro. Also the correct handling and preservation of blood samples is extremely 
important, since even room temperature can activate complement, despite EDTA plasma.  
1.10.2 Complement in APS 
Research so far talks for a role of complement activation in the pathogenesis of 
APS37,103,105,122,274,278-301.  
In 1992 Davis et al demonstrated higher levels of sC5b-9 in aPL+ patients affected by stroke 
compared to other stroke patients aPL-299.  
The following years were characterized by research on APS mice models, where thrombosis 
or fetal injury could be induced by passive transfer of IgG aPL isolated from human sera of 
aPL+ patients. It was important to demonstrate a direct pathogenic role of aPL, but also the 
role of complement was studied in this context. Mice were treated with C3, C5a or fBb 
inhibitors, like C3 convertase inhibitor complement receptor 1 related gene/protein y (Crry)-
Ig103,282, or knocked out for C3, C4 or C5279,280,283. Through these experiments, it was 
possible to show that, when complement is impaired/blocked, mice are protected from fetal 
loss and growth retardation. Moreover, they have a decreased thrombus size and less 
endothelial activation283,284, as expressed by less leucocyte adhesion on endothelial cells. 
Even the anti-complement properties of heparin supported the role of complement in the 
pathogenesis of fetal injury in APS110,280,282,283,293 (see section 1.10.6).  
After mice models, placentas of aPL+ pregnant women were examined for complement 
deposits and signs of damage, with controversial results122,278. Through these studies, it was 
possible to demonstrate the presence of aPL deposits in human placentas.  
Finally, plasma levels of complement factors and inhibitors were measured in primary and 
secondary non-pregnant APS287,289,293,294,302, showing signs of complement activation. In 
particular, Oku et al293 in 2009 demonstrated higher mean levels of complement activation 
products C4a, C3a and Bb, and lower C3, C4 and CH50 (complement hemolytic serum 
activity defined by the serum concentration that results in complement-mediated lysis of 
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50% of sensitized sheep erythrocytes) in pAPS compared to healthy as well as other non-
SLE autoimmune disease-affected controls. No defects in complement factor I (CFI) or 
complement factor H (CFH) were found, but these complement regulators were not 
measured in the whole cohort and they were not compared with controls. The presence of 
anticoagulant treatment was not taken into account in the analysis. However, no patients 
receiving heparin or its derivatives were included in the study. Devreese et al in 2010289 and 
Breen et al in 2012287 found higher levels of C3a both in LA+ and aPL+ patients. The former 
study did not consider treatment in the analysis and the findings were independent of 
previous thrombotic events, whereas the latter showed no difference according to both 
treatment and clinical manifestations. Stachowicz et al190 in 2018 showed higher C3a, C5a, 
sC5b-9 levels in plasma and more C5b-9 deposits on clot from APS patients affected by 
VTE, especially TP and LA+, compared to VTE non-APS and healthy controls. 
Other studies focused on complement split products deposits on platelets and erythrocytes, 
correlating them with aCL and LA. Navratil et al in 2006303 noticed an increase in C4d 
deposits on platelets (P-C4d) in SLE that was associated with LA and aCL, SLE disease 
activity (SLEDAI) and C4d deposits on erythrocytes; there was no adjustment for 
anticoagulant treatment. Svenungsson et al304 confirmed these findings on a larger sample by 
showing more P-C4d in SLE compared to matched controls. P-C4d positively correlate with 
plasma C3dg and negatively with C3 and C4. P-C4d associate with thrombosis 
independently of traditional CV risk factors, renal function and steroid treatment. The Odds 
Ratio for vascular events is higher in concomitant LA+, and an interaction was shown 












Davis, Clin Exp 
Rheumatol 1992299 
sC5b-9 13 stroke aPL+ 13 stroke aPL- 
Higher in aPL+ stroke vs aPL- 
(p=.0018) 






aPL+ sera aPL- sera 
aPL+ sera induced C5b-9 
production, binding to CL-
beads, and platelets activation 
and destruction. Higher titers, 
higher C5b-9 production and 
binding. Monoclonal antibodies 
anti-C5b-9 inhibited platelets 
activation and destruction 
Salmon, Annals of the 
Rheumatic Diseases 
2002103 





injected with control 
IgG or aPL IgG +, 
Crry-Ig  
or C3-/- 
Fetal resorption and growth 
retardation aPL IgG-induced, 
prevented by Crry-Ig. C3-/- 
protected. Absence of C3 
deposits after Crry-Ig 






with aPL IgG 
Mice injected with 
healthy control IgG 
5-fold increase in thrombus size 
in aPL IgG, reversed by Crry-Ig 





human aPL IgG 
Pregnant mice injected 
with F(ab)2 fragments 
of aPL IgG 
C4-/-, C5-/-, anti-C5 mAb, 
C5aR-/- and neutrophil 
depletion protected from fetal 
loss and growth restriction aPL 
IgG-induced (classical pathway 
activation by Fc portion) 





human aPL IgG 
Pregnant mice injected 
with control healthy 
human IgG 
Increased frequency in aPL IgG 
(p<.001), same to controls when 
treated with heparin 
(complement inhibitory 
properties), but not with hirudin 
or fondaparinux. Higher plasma 
C3a and C3 placental deposits in 
mice injected with aPL IgG, 










injected with  
aPL IgG 
C3+/+ and C5+/+ 
injected with control 
IgG. C3-/- and C5-/- 
mice or anti-C5 mAb 
Larger thrombi and more 
leukocyte adhesion in aPL+ vs 
controls. Smaller thrombus size 
in C3-/- and C5-/- or in mice 
treated with anti-C5 mAb 
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occlusions (TOs) in 
intraperitoneal 
injection of LPS 3 
hours before 
Mice injected 
with aPL IgG 
Mice injected with 
anti-β2GPI-depleted 
aPL IgG. C6-/- mice. 
anti-C5 monoclonal 
antibodies (mAb) 
Higher PLAs and TOs in aPL 
IgG, more C3 and C9 deposits. 
Less PLAs and TOs in C6-/- and 
in anti C5-mAb treated mice 
Navratil, Arthritis & 
Rheumatism 2006303 
C4d on platelets  
(P-C4d) 
105 SLE, mean 
age 49.5 years, 
all women, 50% 
aPL+ (just 50% 
of the patients 
were tested) 
115 AI, 65% women 
(including HCV n=23, 
hematologic 
malignancies n=8, 
sickle cell anemia 
n=8, primary Raynaud 
n=5, Sjögren n=5), 
100 healthy, 85% 
women, mean age 40 
years 
P-C4d specific for SLE, 18% of 
SLE, associated with LA+ 
(p<.0001) and IgG aCL+ 
(p=0.035), low serum C4 
(p=0.046) and C4d on 
erythrocytes (p<.0001). 31% of 
aPL+ had P-C4d vs 11% aPL-. 
No correction for /info on 
treatment 
Cavazzana, J of 
Autoimmunity 2007278 
C3c, C4d placental 
deposits 








Infarcts and fibrin deposition in 
APS. No difference in 
complement deposits (APS 
treated with LMWH) 
Shamonki, Am J Obstet 
Gynecol. 2007122 




23 normal placentas 
Higher C4d (p<.001) and C3b 
(p=.005) in aPL+ trophoblasts 
vs controls (that had some 
anyway). Higher C5b-9 
(p=.005) in controls. 62% of 
aPL+ had pathological placentas 
(infarcts, inflammation, 
thrombosis, vasculopathy) vs 0 
controls (p<.001). Those 
abnormalities correlated with 
C4d deposits on trophoblasts 
(p<.001) 
Oku, Ann Rheum Dis. 
2009293 
C3, C4, CH50, C3a, 
C4a, C5a, CFI, CFH 
(EDTA) 
36 pAPS, 75% 
women, mean 
age 46 
42 AI non-SLE (88% 
women, mean age 
52), 36 healthy 
C3, C4, CH50 lower (p<.001) 
and C3a, C4a (measured in 17 
pAPS, 9 AI non-SLE and 15 
healthy) higher in pAPS vs other 
groups (p<.001). No diff in C5a. 
No low CFI, CFH (just 
measured in 13-16 pAPS).  
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CFH ↑ for ↑ C3a, NS (r=0.43, 
p=0.097), CFI ↑ for ↑ C3a, NS 
(r=0.38, p=0.22). Serum 
immune-complex levels higher 
in pAPS vs AI (70% vs 36%, 
p=0.012). High LA+ (OR 6.42, 
95%CI 1.37-30.1) and IgG 
aPS/PT (OR 8.0, 95%CI 1.69-
38.0) inversely correlated with 
CH50. No difference according 
to APS manifestations. No 
adjusted analysis for treatment 
(but no heparin-treated)  






fixation), aPL, no 




51 sAPS, 57 
aPL carriers, 96 
pAPS 
(Sapporo). 
Mean age ca 40, 
women ca 80% 
50 healthy 
IgG aPL and IgG anti-β2GPI  
(p<.05), platelets activation 
(p<.005) and arterial thrombosis 
in SLE-aPL+ (p=.04) positively 
associated with complement 
fixation. No treatment 
adjustment (heparin-treated 
patients excluded, more 
warfarin treated in apL+), no 
adjustment for serum 
complement levels (C4) 
Devreese, Thrombosis and 
Haemostasis 2010289 
C3a (citrate plasma) 





19 LA+ w/o 
thrombosis, 
10 healthy, 12 AI 
aPL- 
Higher in LA+ vs AI and 
controls (p=.0001), higher in AI 
vs controls (p=.0127). No 
difference between LA+ 
thrombosis vs LA+ non-
thrombosis (p=0.47) 










6/15 sAPS, 6/21 
pAPS) 
 
Mice treated with 
normal human IgG; 
mice deficient in C1q 
and factor D. 40 
human healthy 
placenta controls. 22 
Intra-Uterin fetal 
Death (IUFD) non 
APS/SLE 
Increased C4d deposits in mice 
aPL+ vs normal IgG or 
complement deficient, 
associated with adverse fetal 
outcome. C4d diffuse staining in 
SLE/APS (p<.001) vs focal 
staining in IUFD vs none in 




Breen, Thrombosis and 
haemostasis 2012287 








Higher vs controls. No 
difference between clinical 
phenotypes of aPL+ or 
according to treatment 
Stachowicz, Sci Rep 
2018190 
C3a, C4a, C5a, C5b-
9 in plasma, C5-9 
within clots prepared 
ex vivo 
23 APS, 65% 
TP 
19 VTE (no difference 
in treatment vs APS), 
20 healthy, age and 
sex matched 
Higher C3a, C5a, C5b-9 in 
plasma APS vs VTE and 
healthy controls (p<.0001). 
Higher C5-9 content and 
decreased antithrombin in clots 
APS, exp LA+ and TP, vs VTE 
and healthy. Plasma C5b-9 
positively correlated with C5-9 





cytometry), aPL, LA 308 SLE 
308 age, sex and 
region matched 
controls 
Increased in SLE (50% vs 5%, 
p<.0001). Positively correlated 
with C3dg (rs=0.46, p<.0001) 
and negatively with C3 (rs=-
0.28, p<.0001) and C4 (rs=-0.35, 
p<.0001). Adjusted OR for 
thrombosis 2.4 (95%CI 1.3-4.6, 
p=0.006), interaction with LA+, 
OR 12.0 (5.4-28.3), AP 0.8 (0.4-
1.1), RERI 9.2 (-0.7-19.2). No 
correction for/info on 
anticoagulants 
Chaturvedi, Thrombosis 
and Hemostasis 202036 
Cell surface C5b-9 
deposits. 
Complement-
mediated cell killing 
(mHam assay, 
positive when >20% 
cell killing)  
59 pAPS (37% 
TP), 10 CAPS 
74 SLE 
85.7% in CAPS, 35.6% mHam+ 
in pAPS, vs 6.8% in SLE 
(p<.001, for trend). 60% in TPs 
vs 33% in others (p=.002). 
66.7% in recurrent thrombosis 
vs 33.3% in single event 
(p=.001). anti-β2GPI from pAPS 
induced C5b-9 deposition, 
which correlated with mHam 
assay, inhibited by anti-C5 
monoclonal antibodies. No 
effect on mHam or inhibition of 




1.10.3 Complement inhibitors in APS 
The main function of complement inhibitors is the regulation of complement activation. 
Additionally, some of them interact with the enzymes involved in the coagulation process, 
cell adhesion and extracellular matrix306-308. C4BP, Complement factor I (CFI), C1 inhibitor 
(C1INH) act preferentially on the classical and lectin pathways, whereas Complement factor 
H (CFH) and Factor H-like protein 1 (FHL1), among others, act on the alternative pathway. 
TAFIa directly inactivates the split products C3a and C5a of the common final pathway of 
the complement cascade. All these aforementioned molecules are fluid phase complement 
inhibitors. In addition, Decay Accelerating Factor (DAF, or CD55), Complement receptor 
type 1 (CR1, also known as CD35), Complement regulator of the Immunoglobulin 
superfamily (CRIg), Membrane cofactor protein (MCP, or CD46) and protectin (CD59) are 
some examples of membrane-bound regulators (figure 6). 
Impaired function of complement inhibitors may represent one of the additional mechanisms 
leading to excess complement activation and development of an inflammatory process in 
APS. It is therefore of relevance to investigate if aPL have a direct inhibitory effect or if they 
are associated with a decrease in complement inhibitors and if this could contribute to the 
pathogenesis of thrombosis and/or obstetric morbidity in APS. 
In an old study by Hammond et al309, decreased numbers of CR1 molecules on erythrocytes 
in SLE patients with positive aCL and in pAPS was shown. CR1 is a cofactor for factor I in 
the catabolism of C3b, iC3b and C4b. Its impairment may contribute to increased 
complement activation. This study reported a negative correlation between aCL titers and 
CR1, and a positive association between aCL and C3d deposits on erythrocytes.  
The studies that followed were conducted on pregnant mice. In rodents, C3 convertase 
inhibitor complement receptor 1 related gene/protein y (Crry) is a membrane-bound 
complement classical pathway inhibitor, which blocks C3 and C4 activation on self-
membranes. It is essential for early embryonic development and survival310. If absent, 
embryonic damage occurs leading progressively to death, since these embryos are not able to 
suppress the spontaneous complement activation and tissue damage promoted by C3. This 
was shown by both the presence of increased C3 split products deposits on placentas in case 
of absence of Crry, and also by the normal pregnancy outcomes in mice knocked out for both 
Crry and C3. An experimental study by Holers et al282 was able to demonstrate that the 
simultaneous administration of IgG aPL and Crry-Ig in mice during pregnancy totally 
prevented fetal resorptions and growth retardation as compared with IgG aPL treatment only, 
which instead caused a nearly four-fold increase in fetal loss. Moreover, the decidual tissue, 
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which after the injection of IgG aPL was damaged with increased cell density, focal necrosis, 
apoptosis, and scattered clusters of neutrophils throughout, was normal in mice who received 
Crry-Ig together with IgG aPL.  
Subsequent studies on obstetric APS reported a significant reduction in the endometrial 
expression of DAF/CD55 in aPL+ women with recurrent pregnancy loss37, and mutations in 
genes encoding for complement regulatory proteins in pre-eclamptic aPL+/SLE women38. 
Finally, a recent study by Chaturvedi et al36 reported a 60% frequency of mutations in genes 




Table 5 – Studies on complement inhibitors in APS 
Author, Journal, 
Year 
What Study subjects Controls Findings 
Hammond, Arthritis rheum 
1989309 
CR1 and C3d on 
erythrocytes 
8 pAPS, 19 SLE aCL+ 
(tot 27 aCL+) and 34 
SLE aCL- 
33 healthy 
Reduced number of CR1 
molecules in aCL+ vs aCL- 
and in SLE aCL-vs ctrls 
(trend). CR1 negatively 
correlated with aCL titers. 
Higher C3d deposits on 
erythrocytes in aCL+ vs 
aCL- and in SLE aCL-vs 
ctrls (trend). C3d correlated 
with aCL titers. 
Xu, Science 2000310 Crry Crry-/- mice 
C3-/- and 
Crry-/- mice 
Total embryonic lethality, 
more C3 deposits, reversed 
when also C3-/- 




aPL+ women with 
recurrent miscarriages 
in endometrium before 
conception 
aPL- women Lower expression 





pregnant SLE and/or 
aPL+ 
34 matched  
7/40 (18%) pre-eclamptic 
had heterozygous mutations 
vs 5/59 (8%) non-
autoimmune pre-eclamptic. 
No mutations in controls or 
non-pre-ecamptic 
 
Chaturvedi, Thrombosis and 
Hemostasis 202036 






10 CAPS, 55 APS 
21 SLE aPL-, 33 
acquired Haemolitic 
Uremic Syndrome 
(aHUS), 43 healthy 
60% of CAPS had 
mutations in genes involved 
in complement regulation, 
51.5% in aHUS, 21.8% in 
APS (p=.01), 28.6% in SLE 







1.10.4 C4b-binding protein in APS and similarities with β2 glycoprotein I 
C4b-binding protein (C4BP)311-325 is a soluble classic/lectin pathway complement inhibitor 
with anticoagulant properties. Like CFH, the main soluble inhibitor of the alternative 
pathway, it acts on the C3 and C5 convertases in two ways:  
1. with a “decay accelerating activity”, speeding up the dissociation of C4b from C2a 
2. with a “factor I-cofactor activity”, helping CFI in the cleavage and consequent 
deactivation of C4b into fragments (C4c, C4d)326 
C4BP is a glycoprotein synthesized in the liver. It has an octopus shape with a central, ring-
like core, and seven long tentacles (α-chains), plus one shorter (β-chain) in its major isoform 
(α7/β1), which constitutes the 80% of the total (t) C4BP present in circulation (figure 8). 
Other isoforms lack the β-chain or have just six α-chains: α6/β1 (that we call C4BPβ+ 
together with α7/β1, to indicate the presence of the β-chain), α6/β0 and α7/β0. The α-chains 
are composed of eight and the β-chain of three Complement Control Protein (CCP) 
modules312,314.  The β-chain forms a complex with anticoagulant protein S327, whereas each 
α-chain binds to C4b and has high affinity for negatively charged phospholipids311,313,316. 
This feature allows C4BP to localize its complement inhibitory activity near membranes319. 
During inflammation, the synthesis of C4BP isoforms lacking the β chain increases. That’s 
why C4BP α6/β0 and α7/β0 are considered acute-phase reactants. C4BP binds to late 
apoptotic cells to avoid excessive inflammation, by limiting local C3 and C9 
deposition321,324,325. Deficiency in C4BP expression can lead to miscarriages328 and the 
genetic locus C4BPB/C4BPA (separate for the β- and α-chains, respectively) has been linked 





Figure 8 - C4b-Binding Protein (C4BP) 
C4BPβ+ is a spider-like molecule composed of multiple identical α-chains made of eight 
CCPs each and one β-chain made of three CCPs. The chains are disulfide linked in the 
center. The illustrated isoform is the most abundant in the circulation (α7/β1). Each α-chain 
contains a binding site for C4b involving the first three CCP domains, whereas the first two 












In a pilot proteomic study329 we recently noted that C4BP is lower in aPL+ SLE patients as 
compared to SSA/SSB+ SLE patients and controls. Barnum et al330 showed higher plasma 
levels of C4BPt in inflammation and in active SLE compared to healthy controls. This can 
be explained by the fact that the C4BP isoforms lacking the β-chain behave as acute-phase 
reactants. Forastiero et al331 in 1994, measured C4BP in different aPL+ subgroups, showing 
that lower levels are associated with aCL positivity but not with LA+, independently of 
thrombosis or SLE.  
By molecular structure and functions, C4BP is very similar to β2GPI. They both belong to 
the CCP superfamily, together with CFH, CR1/CD35, MCP/CD46, DAF/CD55, protectin 
(CD59), CRIg. The proteins of this particular family are characterized by a structure made of 
CCPs, also called short consensus repeats (SCRs) or sushi-domains, and by flexible 
conformations that have an impact on their functional activity. Conformational changes are 
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influenced by the microenvironment composition, altered by bacterial or viral products, 
inflammation and oxidative stress. As a member of this superfamily, β2GPI regulates 
complement by facilitating C3 degradation332. Moreover, it is a scavenger of 
lipopolysaccharide, playing a role in innate immunity333. Since its plasma levels have been 
shown to be inversely correlated with markers of inflammation as well as temperature rise333, 
it is considered a negative acute-phase reactant. It binds liposomes and microparticles 
(MPs)96 and it is involved in regulation of apoptosis and angiogenesis61. It is involved in 
hemostasis because it interferes with platelets adhesion85,86, ADP-induced aggregation334, 
fXa, fXII and the intrinsic coagulation pathway335. It seems to interact with anticoagulant 
protein C in vitro220 and with tPA, plasminogen and plasmin, enhancing fibrinolysis107. 
Nevertheless, a nicked form of β2GPI, cleaved by plasmin in domain V, has been found to 
bind to plasminogen and to prevent its conversion to plasmin by tPA336, in a sort of negative 
feedback loop to inhibit further plasmin generation. It is downregulated in the acute phase of 
thrombosis in vivo, especially in DIC together with protein C and antithrombin (AT)337. 
Despite all these indications of interaction, it is yet not clear what role exactly β2GPI plays in 
the coagulation network in vivo. Moreover, β2GPI is involved in the regulation of protein S 
activity, because it interferes with the binding of protein S to C4BP338,339, increasing the 
portion of circulating free protein S available for anticoagulation. Human monoclonal 
aCL/anti-β2GPI were shown in vitro to reverse this effect by binding to β2GPI, thereby 
increasing the affinity of PS to C4BP338.  
Due to the similarities between β2GPI and C4BP, the presence of antibodies against C4BP in 
APS is a justified hypothesis. Such antibodies have been detected by Guerin et al340 and 
Arvieux173 in the late -90s, together with antibodies directed towards other CCPs, such as 
anti-CR1 and anti-CFH. Nevertheless, these antibodies haven’t been included in the 
classification criteria, because of their not proven association with thrombosis. Antibodies 
directed to C4BP could possibly contribute to the lower levels of C4BP in aPL+, together 




Table 6 – C4BP in APS 




21 SLE, 100% 
women 
19 patients 24-72h after 
joint replacement 
surgery (acute phase) 
and 33 healthy 
Higher in acute-phase vs 
SLE and controls (p<.0001), 
higher in SLE vs controls 
(p<.0001). No correlation 
between C-reactive protein 
and C4BP 
Parke, the American Journal 
of Medicine 1992341 
C4BP, total PS, 
free PS 
11 obstetric aPL+, 
all women, 
childbearing age. 




(number not known), 
childbearing age, no 
contraceptive 
Lower free PS in aPL+ vs 
controls (p<.05), further 
decrease in pregnancy. Also 
the ratio free/total PS was 
lower in aPL+, positively 
correlated with C4BP. No 
difference in total PS and 
C4BP. No antibody to PS 
was found.  
Forastiero, Blood coagulation 
and fibrinolysis 1994331 
C4BP, total and 
free PS 
73 aPL+ (65/73 
LA+, 53/73 aCL+, 
45/73 both, 20/73 
only LA+, 8/73 
only aCL+), 56% 
women, mean age 
47 years, 16/73 
SLE 
44 healthy, 55% 
women, mean age 39 
years, 
10 SLE-aPL-, 17 
recurrent thrombosis 
aPL- 
Lower levels of C4BP, free 
and total PS in aCL+ vs 
aCL- and controls. C4BP 
lower in aPL+ independently 
of thrombosis (p<.05) or 
SLE (p<.001). Free PS lower 
in aPL+ independently of 
thrombosis (p<.01), in SLE 
aPL+ vs SLE aPL- (p<.001), 
and in SLE aPL- vs controls 
(p<.05). Only free PS was 
different in LA+ vs LA-. No 
subject was on 
anticoagulation 




19 APS anti-β2GPI - 
74% (14/19) anti-CFH 
antibodies 
74% (14/19) anti-CR1  
42% (8/19) anti-C4BP  
32% (6/19) all four 
Arvieux, Blood 1999173 aCL specificities 
6 aCL+ women 
anti-β2GPI negative 
- 






1.10.5 C4BP, protein S and coagulation 
The β chain on C4BP contains the single binding site for protein S (PS). Circa 60% of PS is 
bound to C4BP in plasma, whereas 40% circulates free. Calcium potentiates the interaction 
between C4BP and PS, increasing the strength of their association. PS has high affinity for 
negatively charged phospholipids, therefore localizing the anti-complement actions of C4BP 
near membranes. 
PS is produced by the liver, endothelial cells and megakaryocytes. The main function of PS 
is anticoagulation through acting as a co-factor for activated protein C (APC) in the 
proteolytic cleavage and inactivation of fVa and fVIIIa342. FVa accelerates the conversion of 
prothrombin to thrombin catalyzed by fXa in the prothrombinase complex. Levels of 
anticoagulant PS are reduced in aPL+ patients221,331,343-346 and during warfarin 
treatment342,347-351 (table 7), independently of thrombosis or SLE features. Antibodies against 
PS have been found among the heterogeneous pool of aPL352-354. The presence of these 
autoantibodies creates an acquired deficiency that may partially explain the pro-coagulant 
state characteristic of APS341,346. 
The anticoagulant properties of PS change according to its distinct forms. Free PS is believed 
to be more efficient than the bound state, PS-C4BPβ+. This is explained by the fact that 
C4BPβ+ modifies the activity of PS as cofactor for APC on fVa inactivation.  
APC cleaves fVa at three sites, Arg506, Arg679 and Arg306, and proceeds via a biphasic 
reaction: a rapid proteolysis at Arg506 that results in the formation of an intermediate with 
partial cofactor activity for fXa, followed by a slow cleavage at Arg306, which leads to a total 
inactivation of fVa.  
FXa, in a sort of positive feedback loop, protects APC-mediated cleavage of fVa at Arg506. 
One of the functions of PS is to abolish this inhibition by fXa on APC. Free PS also 
accelerates the APC-mediated cleavage at Arg306. PS also increases the affinity of APC for 
anionic phospholipids, which are necessary for fVa cleavage.  
In the ‘90s313,318,320 it was believed that PS cofactor activity was totally impaired by the 
binding to C4BP. In 2008 Maurissen et al323, by means of different experimental conditions, 
were able to show that the complex PS-C4BPβ+ actually increases Arg306 proteolysis more 
than 10-fold and inhibits Arg506 cleavage by APC by 3-4-fold. Free PS instead stimulates 
Arg306 proteolysis more than 20-fold and has no effect on Arg506, although a 4- to 5-fold 
stimulation of the proteolysis on Arg506 by APC can be achieved, depending on the 
 
 55 
experimental design. The total net effect of PS-C4BPβ+ complex is therefore just a 6-8-fold 
reduction in fVa inactivation as compared to free PS (figure 9). The different amino acid 
targets between free PS and PS-C4BPβ+ also influence the speed of fVa inactivation.  
To summarize, both bound and free PS inactivate fVa, but the site of proteolysis, and the 
amount and speed of inactivation differ between free PS and the complex PS-C4BPβ+, 
consequently affecting the degree of anticoagulation. 
Figure 9 – APC-mediated inactivation of fVa by free and bound protein S at Arg306 and Arg506 
Both PS and PS-C4BPβ+ are cofactors for APC in the proteolysis of fVa. PS enhances the 
cleavage at Arg306 by 18-fold, bound PS by 11-fold. While PS has no effect on APC-mediated 
inactivation at Arg506 in fVa, the complex PS-C4BPβ+ specifically inhibits APC-mediated 





















1.10.6 Anticoagulants355 and complement 
Heparin: Heparin is a natural, highly sulfated polysaccharide that needs binding to 
antithrombin (AT), an endogenous anticoagulant glycoprotein synthetized by the liver, to 
exert its anticoagulant effects, therefore it is considered an indirect anticoagulant. The 
complex heparin-AT inhibits fXa and, to a minor extent in LMWH compared to UFH, 
thrombin (fIIa). It is known since 1929 that heparin has both anticoagulant and complement 
inhibitory properties, thanks to its Oxygen (O) and Nitrogen (N) sulfation356-358. A relevant 
finding in the field of APS was brought by Girardi et al 281 with their experimental study 
conducted on pregnant mice in vivo and confirmed in vitro. They reported that even sub-
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anticoagulant doses of heparin are able to block the complement activation induced by IgG 
aPL, consequently preventing miscarriages in mice. In contrast, other anticoagulants like 
hirudin or fondaparinux that lack complement inhibitory properties, are not able to prevent 
fetal injury, despite efficacious anticoagulation. They also demonstrated a negative 
association between heparin/LMWH and the complement activation product C3a in mice. 
The complete lack of benefit of anticoagulation on fetal resorption has been a striking and 
unexpected finding, because the treatment for thrombosis in APS has been based on 
anticoagulation since the discovery of the syndrome. Moreover, experimental studies show 
that heparin is able to bind to β2GPI via its fifth domain and enhance plasmin-mediated 
cleavage of the Lys317-Thr318 site in β2GPI. In this way, heparin competes with β2GPI’s 
phospholipid-binding site, making it less able to recognize phospholipids, thus decreasing its 
immunogenicity62.  
Warfarin: Studies on the direct effect of warfarin on complement are lacking. Nevertheless, 
by understanding its mechanism of action, it is possible to hypothesize how warfarin might 
influence the complement system. Warfarin inhibits all vitamin K-dependent factors, both 
pro- (fII, fVII, fIX, fX) and anti-coagulants (protein S and C) through the block of the 
vitamin K epoxide reductase complex 1 (VKORC1). This enzyme has the function of 
bringing back vitamin K from an oxidative state (KO) to a reduced state (KH2). The reverse 
process of vitamin K epoxidation is performed by another enzyme, the gamma-glutamyl 
carboxylase, which, at the same time, is involved in the post-translational modification359 of 
vitamin K-dependent proteins. The epoxidation and carboxylation reactions are called 
“coupled reactions”, because carboxylation can only proceed if the gamma-glutamyl 
carboxylase is able to oxidize vitamin K at the same time. The gamma-carboxylation of the 
glutamic acid (Glu) residues in the NH2 terminal molecular region of a protein is necessary 
for its proper release and activation. Since warfarin blocks VKORC1, KH2 is no more 
available to start another epoxidation/carboxylation reaction. This results in the synthesis of 
uncarboxylated or partially carboxylated forms that are biologically inactive. Thus, warfarin 
cannot inhibit proteins that are already in the circulation, rather its anticoagulant effect will 
start after some time. This time variates depending on the half-life of each vitamin K-
dependent factor. Since protein C and S have a shorter half-life compared to vitamin K-
dependent coagulation factors, a paradoxical hypercoagulable state characterizes the first few 




Figure 10 – Warfarin mechanism of action 
KO is the oxidative state of vitamin K, KH2 the reduced form. The epoxide reductase is the 
enzyme inhibited by warfarin, which brings back KO to its reduced state. Gamma-glutamyl 
carboxylase has a coupled function: the oxidation of KH2 together with the γ-carboxylation 










C4BP is linked to protein S in a complex, so it is reasonable to hypothesize that the whole 
complex may be reduced by warfarin treatment. Some old studies confirm this hypothesis 
(table 7). Takahashi348,349 and Bertina342 in the ‘80s reported between 6% and 14% decrease 
in C4BP plasma levels in patients treated with warfarin, as well as in liver disease. Zöller et 
al360 in 1995 showed that plasma levels of both C4BPt and C4BPβ+ are 25% reduced by 
warfarin, a somewhat higher percentage compared to the previous findings. This difference 
can be due to different analytical methods, intensity of anticoagulation and patient selection.  
Direct Oral Anti Coagulants (DOACs): DOACs are small molecules that directly inhibit a 
specific coagulation factor: Xa for Rivaroxaban, Apixaban, Edoxaban, thrombin (IIa) for 
Dabigatran. They have a much shorter half-life compared to warfarin, they are eliminated by 
the kidneys to some extent (80% dabigatran, 25-50% the others) and they do not require 
coagulation monitoring in clinical practice. Moreover, they interact much less than warfarin 
with food or other drugs. The only study that draws conclusions about an effect of 
rivaroxaban on complement is by Arachchillage et al361, where they hypothesize that 
rivaroxaban may have anti-complement properties through the inhibition of fXa. They show 
that complement factors C3a, C5a, sC5b-9 are increased in APS patients affected by 
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previous VTE as compared to healthy controls, irrespective of the anticoagulant used. 
Moreover, they report a reduction of complement activation markers (apart from factor Bb) 
after the switch from warfarin to rivaroxaban. Nevertheless, no correlations were found 
between complement activation factors and rivaroxaban. They concluded in favor of their 
initial hypothesis. On the contrary, an alternative interpretation, based on the mechanism of 
action of these two different classes of anticoagulants, might be that it is warfarin that 
activates complement, whereas the switch to rivaroxaban promotes a normalization of 
complement activation product levels (C3a, C5a, sC5b-9). It’s also interesting to notice that 
mainly the classical pathway is activated, since levels of factor Bb are unchanged. This may 
confirm that the mechanism by which warfarin increases complement activation markers 




Table 7 – warfarin, protein S and C4BP 
 
Author, Journal, Year Patients Controls Findings 




9 liver disease, 13 
DIC, 45 healthy 
Reduced C4BP (6-14%) on warfarin, DIC and 
in liver disease. PS ca 40% reduced on 
warfarin, only slightly reduced in liver 
disease. The intensity of anticoagulation 
(INR) did not affect the amount of reduction 






Reduced PS (ca 40%) and C4BP (6%) on 
warfarin. C4BP positively correlated with 
total (r=0.7) and free PS (r=0.4). PS correlated 
with all the others vitamin K-dependent 
coagulation factors, also decreased on 
warfarin. PS reduction on warfarin seemed to 
be dependent on the intensity of 
anticoagulation (but high variability) 
Takahashi, Clin chim acta 
1989348 
51 warfarin 
39 DIC, 34 liver 
disease, 17 
autoimmune 
disease (11 SLE), 
17 diabetes, 43 
healthy 
Reduced C4BP (6-14%) and reduced PS total 
and free (ca 40%) on warfarin. The reduction 
of both free and total PS on warfarin seemed 
to be dependent on the intensity of 
anticoagulation. Reduced C4BP and PS in 
liver disease and higher in diabetes. Elevated 
C4BP in DIC. C4BP positively correlated 
with total and free PS. PS slightly higher in 
men vs women 













C4BPt and C4BPβ+ 25% lower in 
anticoagulated controls vs non-anticoagulated 
controls, even lower in anticoagulated protein 
S-deficient (ca 30%). PS was 34% lower in 






1.11 Treatment  
aPL profile (e.g. titers, single, double or triple positivity, isotypes, repeated positivity, 
presence of LA), history of past thrombotic/obstetric events, presence of SLE or other 
rheumatic diseases and traditional risk factors for arterial or venous thrombosis or obstetric 
morbidity, are the major determinants for the choice of treatment in APS/aPL carriers.  
The most recent treatment guidelines for APS/aPL have been recently published by the 
European League Against Rheumatism (EULAR)362. 
Primary thromboprophylaxis: For all aPL+ individuals, the presence of other thrombotic 
risk factors or other autoimmune diseases must be considered and treated accordingly. 
Smoking cessation, a proper diet and regular physical activity, counselling on oral 
contraceptive use/postmenopausal hormone therapy, and management of diabetes, 
hypertension and dyslipidaemia are the mainstay. Besides the known effects on blood 
pressure control and kidney function protection, ACE-inhibitors/Angiotensin Receptor 
Blockers also seem to downregulate monocytes TF synthesis and expression in vitro363. 
Statins are potent inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase, involved in cholesterol synthesis in the mevalonate pathway. Besides their lipid-
lowering properties, they can also act as anti-inflammatory and anti-coagulant molecules. 
Experimental studies364-366 have shown that they can reduce the aPL-mediated induction of 
TF, IL-6 and adhesion molecules expression on cultured ECs.  
Hydroxychloroquine (HCQ) should be given to all patients with SLE138. In addition to its 
modulation of the immune system, it is also believed to have anti-thrombotic properties.  
Low dose aspirin (LDA) is recommended in “high risk” aPL profiles (defined as any of the 
following: multiple aPL positivity, LA+ or persistently high aPL titres), and it should be 
considered in non-pregnant women with a history of obstetric APS only and in patients with 
concomitant SLE and low risk aPL profile. 
Low Molecular Weight Heparin (LMWH) at prophylactic dosage is recommended in high-
risk situations such as surgery, hospitalization, prolonged immobilization, pregnancy and 
puerperium.  
Secondary thromboprophylaxis: Warfarin represents the standard and first choice treatment 
of APS. In case of arterial thrombotic events or unprovoked VTE, the treatment should be 
continued indefinitely, requiring regular INR (prothrombin time) monitoring to achieve INR 
values between 2 and 3. It is debated if patients with a history of arterial vs venous events 
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should receive the same treatment or if the target INR should be kept higher in arterial 
thrombosis. In case of provoked VTE and/or low risk aPL profile, shorter treatment may be 
considered in selected cases.  
In case of recurrent event despite reaching the target INR, the addition of LDA, or increase 
INR goal to 3-4 or switch to LMWH is recommended. The choice depends on the individual 
risk profile between bleeding and thrombosis. It should also be taken into account that 
Prothrombin (PT) time is affected by the patients’ diet, other drugs and even by PL/LA, 
although this depends on the reagent used that can be more or less sensitive to LA367. Anyway, 
the influence of LA on the PT test is considered less than on the activated Partial 
Thromboplastin Time (aPTT) assay, because of the much higher PL concentration in the PT 
reagent.  
In this sense, Direct Oral Anticoagulants (DOACs) are easier to manage, since they are 
prescribed in a fixed dose and they do not require monitoring. Nowadays they are indicated 
for VTE and atrial fibrillation in the general population, because they are considered safe and 
effective. Nevertheless, recent randomized controlled trials368,369, case series370-372, and a 
meta-analysis373 have suggested that DOACs should not be used at least in “high-risk” APS 
patients, due to the high occurrence rates of especially arterial thrombosis and even reported 
cases of CAPS374 after the switch from warfarin to rivaroxaban. The “high risk” APS 
patients are defined in the presence of a triple positive aPL profile, a history of arterial 
thrombosis, microthrombosis or organ involvement or in the presence of heart valve disease 
according to Sydney criteria176. DOACs are also contraindicated in APS patients that are not 
adherent to warfarin or with recurrent thrombosis while on therapeutic intensity warfarin. In 
case of “low risk” APS patients, single or double positives, affected by a single episode of 
VTE, further studies are needed to establish the non-inferiority and safety of DOACs as 
compared to warfarin373. 
These are the last recommendations from the Lupus Anticoagulant/Antiphospholipid 
Antibodies Scientific and Standardization Committee (SSC) of the International Society on 
Thrombosis and Haemostasis (ISTH) published last year176, after other recommendations 
issued from different societies (EULAR, EMA, ESC, BSH). 
The first trial, Rivaroxaban in the Antiphospholipid Syndrome (RAPS)375-379, was a non-
inferiority randomized controlled trial (RCT) on APS patients, with and without SLE, 
affected by previous VTE and on permanent warfarin treatment. The triple positive patients 
were 28%. Participants were randomized 1:1 to remain on standard intensity warfarin with 
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target INR 2-3 or to switch to rivaroxaban for 6 months. The primary aim was to 
demonstrate that the intensity of anticoagulation achieved with rivaroxaban is not inferior to 
that of warfarin. The intensity of anticoagulation was assessed by measuring the percentage 
of change from randomization to day 42 of the Endogenous Thrombin Potential (ETP), i.e. 
the Area Under the Curve of thrombin generation, triggered by TF in vitro. Secondary aims 
were to compare rates of recurrent thrombosis, bleeding and the quality of life in patients on 
rivaroxaban with those on warfarin.  
Since the mechanisms of actions of the two drugs are different, the authors wanted to choose 
a laboratory surrogate outcome measure that could be comparable, but the choice of ETP for 
monitoring the intensity of anticoagulation in DOACs has been a subject of debate. Some 
studies support its use as appropriate, even though ETP is intrinsically large in rivaroxaban, 
not really reflecting the degree of anticoagulation in vivo. In fact, rivaroxaban has a targeted, 
specific inhibitory action on fXa, affecting mostly the initiation and propagation of thrombin 
generation, because of a delay in the formation of the prothrombinase complex. This is 
shown by other parameters, such as lag time (time to generate thrombin from TF), time to 
peak thrombin generation (TG) and peak TG (max TG), intrinsically prolonged and lower 
during rivaroxaban treatment. At the endpoint of the trial, the ETP was significantly larger in 
the rivaroxaban group as compared to warfarin, despite the mean percentage change in ETP 
didn’t reach the non-inferiority threshold. Since the peak TG was significantly lower, and lag 
time and time to peak TG were prolonged in the rivaroxaban group, the authors concluded 
for the non-inferiority of rivaroxaban regarding the intensity of anticoagulation. 
Additionally, there were no new thrombotic events, no major bleeding episodes and better 
quality of life was registered in the rivaroxaban group than in the warfarin group. The 
authors concluded that the treatment with rivaroxaban is safe and effective in APS patient 
with previous VTE, irrespective of the aPL profile. 
These conclusions led Pengo et al to start the Trial of Rivaroxaban in the Antiphospholipid 
Syndrome (TRAPS)380,381, a non-inferiority, prospective, randomized trial in high-risk, triple 
positive patients with APS, affected by previous venous, arterial thromboembolism, micro-
thrombosis or obstetric APS. The primary outcome was to assess the non-inferiority of 
rivaroxaban in terms of prevention of thromboembolic events, major bleeding, and vascular 
death. The trial was prematurely stopped because of a much higher rate of 
thromboembolism, all in the arterial circulation (12% vs 0%) and major bleeding (7% vs 3%) 
in the rivaroxaban as compared to the warfarin group. Moreover, a 2-year follow-up from the 
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interruption of the trial showed that the difference in outcomes was even higher, especially in 
terms of thromboembolisms381. The possible causes of rivaroxaban failure may depend on a 
poor compliance or on an insufficient drug concentration, due to a higher inter-individual 
variability in drug metabolism. Moreover, rivaroxaban has a shorter half-life as compared to 
warfarin, which may reduce the anticoagulant effect in patients with poor compliance. In the 
RAPS trial377, only 51% of the patients reached the minimum therapeutic concentration of 
rivaroxaban at their peak, whereas 11% were far below the range. This may imply that 
DOACs are less effective and safe than warfarin when compliance is not good and adherence 
to treatment is even more important than with warfarin, because of their shorter half-life and 
less constant plasma levels. Moreover, the different mechanism of action and a different 
impact on the complement system may contribute to explain the different outcomes of the 
two drugs.  
Apixaban for the Secondary Prevention of Thromboembolism among patients with the 
AntiphosPholipid Syndrome (ASTRO-APS) is an ongoing clinical trial where definite results 
are not available yet, but they seem to be in line with data reported so far, according to the 
last Forum on APS on the 26th of March 2021 in Belgrade. 
In case of obstetric APS382 with recurrent pregnancy complications despite combination 
treatment with LDA and LMWH at prophylactic dosage, LMWH dose can be increased to 
therapeutic dose or HCQ may be added or low-dose prednisolone in the first trimester. 
Intravenous immunoglobulin might be considered in highly selected cases. In women with a 
history of thrombotic APS, combination treatment of LDA and LMWH at therapeutic dosage 
during pregnancy is recommended.  
Long-term treatment with LMWH has apparent disadvantages since it has to be given 
subcutaneously and heparin-induced thrombocytopenia is a rare but life-threatening side 
effect. Nevertheless, in a case series, Vargas-Hitos et al observed no thrombotic recurrences 
in 23 patients on LMWH who failed or did not tolerate warfarin383.  
CAPS merits a special and more aggressive treatment, consisting of a triple therapy with 
anticoagulation, glucocorticoids, plasma exchange and/or intravenous immunoglobulins. This 
therapy is recommended over single agents or other combinations of drugs, according to the 
data collected in the CAPS registry32,384. Additionally, any triggering factor (eg, infections, 
gangrene or malignancy) should be treated accordingly.  
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Future perspectives: Since new pathogenic mechanisms of disease have been elucidated, new 
targets for treatment, apart from coagulation, have been hypothesized and tested in clinical 
practice, mainly in cases of refractory or rapidly progressing CAPS. The two principal tested 
mechanisms are B cell depletion through Rituximab and complement inhibition through 
Eculizumab. Rituximab is a chimeric monoclonal antibody against a surface protein expressed 
on the membrane of B cells (CD20), currently approved for the treatment of chronic 
lymphocytic leukemia, diffuse large B-cell, advanced follicular lymphoma, refractory 
rheumatoid arthritis and severe vasculitis. Eculizumab is a humanized monoclonal antibody 
against C5 convertase, so far successfully employed in case reports with thrombotic 





2.1 General aims 
The aim of this project was to investigate important mechanisms behind thrombotic 
complications in aPL positive individuals and to address differences between patients 
affected by arterial and venous thrombosis. For this purpose, we aimed to study the 
interactions between coagulation, fibrinolysis and complement system in APS patients. 
More specifically, we focused our investigations on the role of the two complement 
inhibitors involved in regulation of coagulation and fibrinolysis, i.e. C4b-binding protein 
(C4BP) and Thrombin activatable fibrinolysis inhibitor (TAFI), respectively.  
Our results led us also to study the effects of different anticoagulants on complement 
activation, bearing in mind that hemorrhage is a quite common side effect, representing ca 
11% of causes of death in APS.  
We were also interested in understanding if APS is really a rare syndrome, or if it’s an 
“under-recognized condition”, since aPL are not routinely tested in clinical practice in 
several specialties that deal with occlusive vascular diseases. According to the 
epidemiological studies by Cervera et al23-25, despite MI was present in 5.5% of patients at 
enrollment, it was reported to be the second most frequent cause of death. Thus, we 
analyzed aPL in a large cohort of patients from the general population affected by 
myocardial infarction (MI) and in matched controls, to study the prevalence of aPL in this 
condition. Moreover, we aimed to see if the presence of aPL makes a difference in terms of 
severity of events or if it can be considered a marker of increased cardiovascular risk.  
2.2 Specific aims 
2.2.1 Paper I 
 Study TAFI and TAFIa in mainly pAPS classified according to Miyakis criteria 
 Correlate TAFI and TAFIa levels to markers of fibrinolysis (CLT and Ks) and 
complement activation (C5a) in different clinical APS manifestations (arterial vs 
venous thrombosis/obstetric morbidity) 
2.2.2 Paper II 
 Assess the prevalence of anti-β2GPI and aCL IgG/A/M in a large multicenter case-
control study comprising 805 first-time MI patients and 805 population controls, 
matched for age, sex and geographical region  
 Compare aPL positive versus aPL negative MI patients in terms of MI 
characteristics, traditional CV risk factors and previous history/comorbidities 
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2.2.3 Paper III 
 Study complement activation, and in particular the soluble complement inhibitor 
C4BPt, in primary and secondary APS patients, and in different subgroups of patients 
affected by SLE 
 Study complement activation, with focus on C4BPt, in relation to anticoagulant 
treatment 
2.2.4 Paper IV 
 Explore the effects of anticoagulants on complement activation, by comparing 
complement protein levels and C4BP in patients from the general population affected 




3 MATERIALS AND METHODS 
3.1 Study design and population 
3.1.1 Paper I 
This is a cross-sectional study on 52 patients (43 women and 9 men, mean age 44 years) 
recruited from the Rheumatology, Haematology and Women’s and Children’s Health clinics, 
Karolinska University Hospital, between 2009-2012. At inclusion, patients filled out a 
detailed questionnaire about their daily habits, clinical history, signs, symptoms and 
treatment, helped by a specialist physician and a nurse; all records were then verified through 
medical file review. Blood samples were collected at the same time. 
Definition of APS clinical manifestations 
Arterial thrombosis: myocardial infarction (MI) was defined as at least two of the following: 
chest pain of typical intensity and duration, ST segment elevation or depression of ≥1 mm in 
any limb lead of the electrocardiogram, of ≥2 mm in any precordial lead, or both, or at least a 
doubling in cardiac enzymes CK, CK-MB, Troponin T. MI was also considered after 
PTCA/CABG intervention. Abrupt onset of a neurological deficit that resolved completely in 
< 24 h was diagnosed as transient ischemic attack. Patients with new neurological deficits 
persisting for >24 h underwent cerebral computerized tomography (CT) scan or magnetic 
resonance imaging to discriminate hemorrhagic and ischemic strokes. Acute peripheral 
arterial thrombosis was diagnosed in the presence of a typical clinical picture (pain, absence 
of peripheral pulse) and confirmed by Doppler ultrasound, angiogram and/or surgical 
intervention. 
Venous thromboembolism: deep vein thrombosis (DVT) confirmed by Doppler ultrasound, 
pulmonary embolism (PE) detected by scintigraphy or angio-CT scan 
Obstetric complications: defined according to criteria2, detected by the obstetric Unit. 
Arterial hypertension was considered present if patients were receiving antihypertensive 
treatment or if arterial blood pressure was > 140/90mmHg at inclusion; hyperlipidemia if the 
available values of total or fractioned cholesterol were not in the reference range at the time 
of enrollment. This choice was based by the fact that not all patients treated with statins are 
dyslipidemic: many are on lipid-lowering treatment as secondary prevention after an arterial 




Definition of laboratory criteria 
aPL positivity was considered when at least one test among lupus anticoagulant (LA), anti-
cardiolipin IgG/IgM isotype (aCL IgG/IgM) at medium/high titer or anti-β2 glycoprotein I 
IgG/IgM isotype (anti-β2GPI IgG/IgM) at titers >99
th percentile of healthy blood donors (free 
from thrombosis/obstetric morbidity and matched for age, sex and place of residence) was 
positive twice. Confirmation tests were performed after a minimum of 12 weeks. We also 
required at least 12 weeks and no more than 5 years between positive testing and the clinical 
manifestation. 
General characteristic of the investigated subjects 
All 52 patients were free from SLE, which was an exclusion criterium. Eight patients also 
fulfilled criteria for other rheumatic diseases: 6 rheumatoid arthritis, 1 ankylosing spondylitis 
with ulcerative colitis, and 1 Sjögren’s syndrome. The 15 healthy controls were recruited 
from our laboratory and none of them took non-steroidal anti-inflammatory drugs (NSAID) 
or acetylsalicylic acid (ASA) for at least two weeks before blood sampling. 
Clinical APS manifestations: 33 (63.5%) patients were affected by a venous thromboembolic 
event, of which 22 (42.3%) deep venous thrombosis (DVT), 18 (34.6%) pulmonary 
embolism (PE). Fifteen patients (28.8%) suffered from ischemic stroke, one of them also had 
a myocardial infarction (MI). Twenty patients (38.5%) had experienced obstetric morbidity. 
Antibody profile: single positives were present in 7/52 (13.5%) for LA, one for anti-β2GPI 
IgG, no single positives for aCL. Half of the patients were triple positives (26/52). 
Further demographic, clinical and laboratory characteristics of the investigated patients are 
presented in table 1 and 2, paper I. 
3.1.2 Paper II 
This study has a cross-sectional, case-control design, and uses the samples of patients and 
controls enrolled in the PAROKRANK study392, a multicenter case-control study on 805 
patients less than 75 years old, recruited between May 2010 and February 2014 from the 
coronary care units of 17 Swedish hospitals. The study was coordinated from the Cardiology 
Unit, Department of Medicine at Karolinska Institutet, Stockholm, Sweden. 
Exclusion criteria were prior MI, prior heart valve replacement and any other condition that 
could limit the ability to cope with the study protocol.  
Controls were individually matched for age, gender and region of living, using the Swedish 
population registry, coded for date of birth and sex. Controls were contacted by a phone call 
by trained research personnel at the PAROKRANK coordinating center, providing study 
information. Controls had to be free from prior MI and heart valve replacement and be 
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willing to participate. Contact information was subsequently sent to the local study center 
where oral and written informed consent to participate was obtained. 
Patients were recruited while hospitalized for MI and scheduled for outpatient visits 6-10 
weeks later at the local department of cardiology. The matched control was recruited from 
the same region as soon as a patient had undergone the follow-up visit at the cardiology 
department in order to perform the investigations during the same season.  
All participants fasted and abstained from smoking for 12 hours before visiting the 
cardiology department where a physical examination including heart rate, blood pressure 
following five minutes of rest in sitting position, height, body weight and waist 
circumference was performed. Questionnaires comprising extensive information on family 
and medical history, risk and health preserving factors were completed both at the time of 
hospital admission for the patients/recruitment for the controls and at follow up. 
Smoking habits were defined as current, previous (stopped >1 month ago) or never. 
Treatment after MI was according to guidelines. 
Clinical and serological characteristics of the investigated subjects are shown in the table in 
paper II. 
3.1.3 Paper III 
This is a cross-sectional study on different subgroups: 
 67 patients affected by pAPS according to Miyakis criteria, and 15 individuals with 
repeated positivity (++) for aPL/LA but without SLE or any thrombotic/obstetric 
manifestations (aPL carriers) were recruited at the Rheumatology, Haematology and 
Women’s and Children’s Health clinics, Karolinska University Hospital, between 
2009-2014.  
 487 patients diagnosed with SLE according to the 1982 revised American College of 
Rheumatology classification criteria were recruited from the Rheumatology 
Department, Karolinska University and Danderyd’s Hospitals between 2004-2014. 
Of those, 118 were repeatedly positive for aPL/LA (SLE-aPL++), of which 56 
affected by sAPS, 291 tested negative for aPL/LA (SLE-aPL-), and 77 were only 
aPL+ once. This last subgroup was excluded from the study to avoid 
misclassifications, since we couldn’t know if these patients would have been 
repeatedly positives, if tested.  
 322 controls were identified through the National population registry and a subgroup 
of 67 was individually matched for age and gender to pAPS patients. No pregnant 
women were included. 
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All participants filled out a detailed questionnaire, including data on smoking history 
(previous smokers if ≥ 1 year without smoking) and treatment, and underwent a physical 
examination, including measurement of systolic and diastolic blood pressure. Hypertension 
was defined as >140/90mmHg or current antihypertensive treatment. All records were 
verified through medical file review. Data on APS clinical manifestations were classified as 
arterial thrombosis, venous thromboembolism (including Deep Venous Thrombosis (DVT) 
and Pulmonary Embolism (PE)) and obstetric manifestations according to criteria2 (see also 
point 3.1.1). We collected data on lupus nephritis (LN) in SLE patients at the time of 
sampling/enrollment, and we recorded it according to both presence and activity, using the 
British Isles Lupus Assessment Group (BILAG) renal score (A most active, E no history of 
LN)393.  
Clinical and serological characteristics of the investigated subjects are presented in table 2 
and 3, paper III. 
3.1.4 Paper IV 
This is a study with a crossover design: each patient was sampled twice, during treatment 
and after withdrawal, so that each patient served as his or her own control (paired samples). 
Comparisons were also made between independent groups of patients with/after different 
treatments. All the enrolled patients belonged to the general population, they had been 
diagnosed with venous thrombosis (VTE) (indication for treatment) and were free from 
autoimmune diseases and cancer. No woman was pregnant at the time of sampling.   
Samples from 22 patients treated with warfarin were collected between 2009-2015. Duration 
between VTE diagnosis and first sampling was in median 120 days and between warfarin 
withdrawal and second sampling 19 days.  
A second cohort of 33 patients on DOACs (11 on apixaban and 22 on rivaroxaban) were 
sampled between 2014-2019, with first sampling in median 74 days after VTE diagnosis and 
second sampling 21 days after DOAC withdrawal.  






3.2 Laboratory investigations 
3.2.1 Paper I 
Blood samples from the APS patients and healthy controls were drawn into 0.129 mol/L 
trisodium citrate and centrifuged at room temperature (for 20min at 2570xg and 2000xg 
respectively) to obtain platelet-poor plasma that was then deep frozen in aliquots of 0.5 mL 
at -70°C to -80°C. Samples were thawed in water bath at 37°C before testing.  
Antibodies against cardiolipin (aCL IgM/IgG) and β2 glycoprotein-I (anti-β2GPI IgG) were 
analyzed by ELISA (Orgentec, Mainz, Germany). Anti-β2GPI IgM were tested with a 
multiplex immunoassay (BioPlex 2200, Bio-Rad Laboratories, Hercules, California, USA) 
Lupus anticoagulant by dilute Russell Viper Venom (dRVVT) method with reagents from 
Biopool, Umeå, Sweden and Gradipore, North Ryde, Australia.  
TAFI (proenzyme) was determined by a chromogenic substrate method (STA® - 
Stachrom® TAFI kit, Diagnostica Stago, France).  
TAFIa (enzyme) was quantified by measuring, through ELISA (Asserachrom TAFIa/TAFIai 
antigen kit, Diagnostica Stago, France), the complex TAFIa/TAFIai, made of both the active 
and inactive forms of the enzyme, which corresponds to the concentration of the active form 
that cannot be measured because of instability. 
C5a was analyzed with a direct-capture immunoassay (MicroVue C5a Enzyme 
Immunoassay, Quidel Corporation, San Diego, USA).  
Thrombomodulin was determined by quantitative sandwich ELISA (Human 
Thrombomodulin/BDCA-3 Quantikine ELISA Kit, R&D Systems Inc. USA). 
Fibrin clot structure was studied in citrated plasma samples by measurement of the 
permeability coefficient (Ks, Darcy constant) through a liquid permeation technique394, 
described below (figure 11). 200 µL of plasma were supplemented with CaCl2 and thrombin 
at final concentrations of 20 mmol/L and 0.2 U/mL respectively, and left in a moisture 
atmosphere overnight in order to allow clot formation in all samples. Thereafter, a 
percolating buffer (pH 7.4, 0.02 mol/L Tris, 0.02 mol/L imidazole, 0.1 mol/L NaCl) was 
passed through the clots at 5 different hydrostatic pressures and the volume of collected 
eluate was measured after an indicated time. Analyses were performed in duplicate.  
The Darcy constant reflects the permeability of the clot by percolating a volume of buffer 
(Q) with a certain viscosity (η) through a fibrin gel (with length L and cross-sectional area A) 
at a given hydrostatic pressure (p) in a given time (t). The formula to calculate Ks is: Q x L x 









Turbidimetric clotting and lysis assays were performed to assess fibrin formation and 
degradation respectively, according to the methods described by Carter et al181. Seventy-five 
µL of assay buffer (pH 7.4, 0.05 mol/L Tris-HCl, 0.15 mol/L NaCl) was added to 25 µl of 
citrated plasma (in duplicate) in a microtiter plate. Fifty µl of a mixture of thrombin (final 
concentration 0.03 IU/mL) and CaCl2 (final concentration 7.5 mMol/L) was added to the 
plasma samples and the absorbance at 340 nm was read every 18 sec (240 cycles for each 
sample). In the turbidimetric lysis assay, recombinant tPA (Technoclone, GmbH, Vienna, 
Austria) was added to the Tris-HCl buffer at a final concentration of 83 ng/ml. CLT was 
defined as the time from the midpoint of the clear–to–maximum-turbidity transition (which 
is defined as clotting time), to the midpoint of the maximum turbid–to–clear transition. It is 
used to estimate fibrin porosity181: the higher time it takes to lyse the clot, the less the 
permeability180,181,394-396. The inter-assay coefficient of variation was 11.4%, intra-assay 
2.3%. 
Fibrinogen was analyzed by nephelometry (BN Prospec nephelometer, Dade Behring, 
Deerfield, IL, USA for 29 patients and Sysmex® CS2100i, Sysmex, Kobe, Japan with 
reagent Dade Thrombin from the Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA 
for 23 patients and healthy controls), a technique based on the quantification of the intensity 





3.2.2 Paper II 
The local laboratories performed the following analyses: complete blood count, P-lipids 
(total and HDL-cholesterol and triglycerides), P-creatinine, P-fibrinogen, P-glucose and 
glycated hemoglobin A1c (HbA1c). Study participants without known diabetes underwent 
an oral glucose tolerance test (75 g glucose in 200 ml water) with venous P-glucose 
measured in the fasting state and two hours after glucose intake. The point-of-care 
HemoCue® 201 System (HemoCue AB, Ängelholm, Sweden) was used for the P-glucose 
analysis. High sensitivity C Reactive Protein (hsCRP) was analysed at a central 
laboratory (Redhot diagnostics, Södertälje, Sweden) by an ELISA method (MP Biomedicals, 
New York, USA) intended for quantitative determination CRP, with the functional 
sensitivity of 0.1 mg/L.  
Antibodies to specific nuclear antigens (dsDNA, SSA Ro-52, SSA Ro-60, SSB, Sm) and 
phospholipids/phospholipid-binding proteins (cardiolipin and 2-glycoprotein I IgG, IgM, 
IgA) were analyzed by multiplexed bead technology (Luminex) using BioPlex 2200 system 
(Bio-Rad, Hercules, CA, USA) according to the specifications of the manufacturer. The cut 
off for aCL and anti-β2GPI fulfills the 99
th percentile as described397.  
3.2.3 Paper III 
At the time of inclusion, blood samples were collected by direct venipuncture, centrifuged at 
2000xg at room temperature for 20 minutes before aliquotation and stored at -80°. Plasma 
levels of inflammatory markers (CRP, ESR, fibrinogen, albumin), renal function (creatinine), 
lymphocytes and platelets were measured according to hospital routines398.  
Antiphospholipid antibodies were analyzed by multiplexed bead technology (Luminex) 
using BioPlex 2200 system (Bio-Rad, Hercules, CA, USA) according to the specifications of 
the manufacturer.  
Lupus anticoagulant was determined using a modified Dilute Russel Viper Venom method 
(Biopool, Umea, Sweden) using Bioclot lupus anticoagulant. 
The total amount of C4BP (C4BPt) was measured using magnetic carboxylated 
microspheres coupled with a monoclonal antibody against the α-chain of human-C4BP 
(BIO-RAD, Hercules, CA, USA). To detect C4BPt the same antibody was used, 
biotinylated. The binding of biotinylated antibodies was detected by streptavidin-
phycoerythrin (PE, BIO-RAD) and data were collected using a MAGPIX Multiplex Reader 
(BIO-RAD). The results are expressed in mg/L. 
Factor I was detected by a magnetic bead assay using a mouse monoclonal anti-Factor I 
antibody (Abcam, Cambridge, UK) for capture and a biotinylated polyclonal anti-Hu-factor I 
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antibody (Abcam) followed by streptavidin-PE for detection using a MAGPIX Multiplex 
Reader. 
C1q was detected by magnetic bead-based sandwich immunoassay (MBSI)399. 
C2 serum concentration was measured by electroimmunoassay400 and the results are given in 
arbitrary units (% of normal human serum pool). 
C3, C3dg, C4 were analyzed according to clinical routine using nephelometry at the 
Department of Clinical Chemistry at the Karolinska University Hospital. The results are 
reported as g/L (normal ranges: C3 0.77–1.62 g/L, C3dg <8 g/L, C4 0.13-0.32 g/L). 
C3a was determined by sandwich ELISA, using mAb 4SD17.3 for capture and biotinylated 
polyclonal anti-C3a, followed by HRP-conjugated streptavidin (GE Healthcare, Uppsala, 
Sweden) for detection. Data are given as µg/L.  
sC5b-9 was quantified with an in-house magnetic bead-based assay using mAb anti-human-
neo-C9 aEII (Bioporto Diagnostics A/S, Hellerup, Denmark) (1.5 g/1.25 *10^6 beads) for 
capture and polyclonal sheep anti-Hu-C5 antibody (BP373, OriGene, Herford, Germany; 4 
g/mL, biotinylated) followed by streptavidin-PE (1:100) for detection. The assay was 
calibrated against a commercially available kit (Quidel, San Diego, CA, USA) and data are 
given as µg/L. 
Free protein S antigen (PS Ag) in citrated plasma samples was performed using Innovance® 
Free PS Ag turbidimetric assay on automated coagulation analyzer BCS®XP, Siemens 
Healthcare Diagnostics (Germany).  
Total protein S was analyzed using Asserachrom® Total Protein S one-step enzyme 
immunoassay by ELISA method, Diagnostica Stago (France).  
3.2.4 Paper IV 
Samples were provided by the Biological Resources Center, Assistance Publique - Hôpitaux 
de Marseille in France (CRB AP-HM, certified NF S96-900 & ISO 9001 v2015). Blood was 
collected in both EDTA and citrated tubes (0.105M sodium citrate): EDTA blood was used 
for routine analysis, complement assays and DNA preparation; citrate plasma was used for 
coagulation assays. All samples were centrifuged within one hour by double centrifugation at 
2000xg for 15 min at room temperature, then stored at -80◦C in aliquots until analyzed. Prior 
to analysis, the samples were thawed in a 37°C water bath, then transferred to an ice bath 
where all dilutions took place. EDTA (10 mM final concentration) was added the first time 
the samples were thawed in order to minimize the risk of pre-analytical complement 
activation, since it has been demonstrated that in citrate plasma one single 5 min cycle of 




Platelet counts and measurement of coagulation parameters, concentration of DOACs, aPL 
(negative for all patients) were performed along with DNA analysis for Factor V Leiden 
(R506Q) and the 20210G-A prothrombin mutation.  
FVIII:C was analyzed using human FVIII-deficient plasma in a one-stage assay using the 
STA®-ImmunoDef VIII kit (Diagnostica Stago, France). Fibrinogen levels were assayed 
using the STA Fibrinogen kit (Clauss method). D-Dimer was measured by the particle-
enhanced immunoturbimetric assay STA®-Liatest®, D-Di PLUS (Diagnostica Stago). Free 
protein S was measured by enzyme-linked immunosorbent assay (ELISA) using the 
Asserachrom FPS assay (Diagnostica Stago, France). INR, derived from Prothrombin Time 
was obtained by using the STA®-Neoplastine CI reagent (Diagnostica Stago) and was used 
to monitor anticoagulant effect of warfarin. Thrombospondin-1 (TSP-1) was measured with 
a commercial ELISA-kit (Duo-Set DY-3074, R&D 9 Barton Lane, Abingdon Science Park, 
Abingdon, UK). Plasmin-α2-antiplasmin (PAP) was measured with a commercial ELISA-kit 
(Duo-Set DY-1407-05, from R&D Systems).     
Plasma concentration of rivaroxaban and apixaban was based on anti-Xa specific activities, 
and measured with an anti-Xa assay calibrated to the specific drug (Biophen Heparin, 
Hyphen Biomed, Neuville-sur-Oise France). All parameters were determined in one sample 
on an automated coagulometer (STA-R; Diagnostica Stago). 
Thrombin generation at 5pM TF and 4M of phospholipids was measured using the 
Calibrated Automated thrombography (CAT) method401, according to manufacturer’s 
instructions. Four parameters were collected from the Thrombinoscope software: lag time 
(minutes), peak (nM), time to peak (minutes) and endogenous thrombin potential (ETP in 
nM/minute) corresponding to the area under the curve which reflects the total amount of 
thrombin generation.  
The CP functional test was assessed by lysis of sensitized sheep erythrocytes402.  
C3a was determined by sandwich ELISA, using mAb 4SD17.3 for capture and biotinylated 
polyclonal anti-C3a, followed by HRP-conjugated streptavidin (GE Healthcare, Uppsala, 
Sweden) for detection. C4a was measured only in warfarin patients with a commercial 
ELISA kit (A036, Quidel, San Diego, CA, USA). sC5b-9 (surrogate marker for C5a 
generation) was quantified with an in-house magnetic bead-based assay using mAb anti-
human neo-C9 aEII (Bioporto Diagnostics A/S, Hellerup, Denmark) for capture and 
polyclonal sheep biotinylated anti-Hu-C5 antibody (BP373, OriGene, Herford, Germany) 
followed by streptavidin-phycoerythrin (PE; BIO-RAD, Hercules, CA, USA) for detection. 
The assay was calibrated against a commercially available kit (Quidel). C1q was detected by 
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magnetic bead assay as previously described399. C3 and C4 (C4 only in warfarin patients) 
were determined with an Immage nephelometer (Beckman Coulter, Bromma, Sweden). 
Since C4BP can exist in different isoforms, in house assays were constructed to quantitate 
the total amount of C4BP. C4BPt (total, including all isoforms), the C4BP isoform that 
contains the β-chain (C4BPβ+), and the complexes between C4BPβ and protein S (PS- 
C4BPβ+) were all measured by magnetic bead-based assays using a BioPlex MAGPIX 
Multiplex Reader (BIO-RAD). For all assays, magnetic carboxylated microspheres (Bio-
Plex, Pro Magnetic COOH Beads, BIO-RAD) were coupled with mAb against the -chain 
of human-C4BP (MCA2609, BIO-RAD) and used to capture the antigen. C4BPt was 
quantified using the same biotinylated mAb. Detection of C4BPβ+ was performed using a 
rabbit biotinylated polyclonal antibody against the -chain (MBS712775, MyBioSource, San 
Diego, CA, USA), and PS-C4BPβ+ was detected with a biotinylated polyclonal sheep 
antibody against human PS (7861-1009, BIO-RAD). The binding of biotinylated antibodies 
was detected by streptavidin-PE (BIO-RAD). The raw data from the BioPlex MAGPIX 
Multiplex Reader, expressed as mean fluorescence intensity (MFI) and the standard curves 
were calculated with a five-parameter regression model using Bio-Plex Manager MP 
Software and Bio-Plex Manager 6.1 (BIO-RAD).  
3.3 Statistics 
Data are presented as mean values ± standard deviation for normally distributed continuous 
variables, and as median (Interquartile Range, IQR) for non-normally distributed continuous 
variables. Data with skewed distributions were logarithmically transformed to obtain 
normality. Percentages and proportions are used to present categorical variables.  
For continuous, normally distributed variables, comparisons were made using paired (when 
matched data) or independent Student’s t-test. Fishers’ exact test and χ2 test, when 
appropriate, were used to compare independent categorical variables, McNemars’ test for 
categorical, matched variables. To assess dependence and strength of associations among 
continuous variables, we used standard least squares linear regression and correlation 
analysis, respectively, to calculate regression coefficients () and Pearson’s correlation 
coefficients (r) for continuous parametric variables; Spearman´s rank correlation coefficient 
(ρ) was used for continuous non-parametric variables. Bonferroni correction was applied to 
multiple comparisons. Multivariable linear/logistic regression analyses were performed to 




Odds Ratios, crude and adjusted for confounders, and corresponding 95% confidence 
intervals were calculated by use of logistic regression, conditional in case of matched pairs. 
Mediation analysis was performed as in Vanderweele and Vansteelandt403 in the SLE patient 
group. The repeated presence of aPL was considered as exposure and C4BPt levels as the 
outcome. Warfarin is a mediator, since its long-term treatment is mostly given to exposed 
(aPL++) patients and its reducing effect on C4BPt has been described in previous studies in 
the general population in the absence of aPL. Warfarin occurs in the causal pathway between 
the exposure and the outcome and it is not a confounder because it is not believed to affect 
the exposure (aPL++). Among the SLE patients, there are both exposed (aPL++) and 
unexposed (aPL-), with and without mediator (warfarin). 
The significance level α was set at 0.05 for hypothesis testing (two-sided), a 95% Confidence 
Interval was reported for the estimation. 
JMP software (SAS Institute, Carey, North Caroline, USA) was used for statistical analysis. 
Mediation analysis was performed with R. GraphPad Prism 8 was used to make graphs.  
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3.4 Ethical considerations 
Paper I, II and III were approved by the Regional Ethical Committee in Stockholm, and all 
the studies were performed respecting the Declaration of Helsinki.  
All the subjects in all the studies gave voluntary informed consent for participating and for 
their blood to be stored anonymously (with an assigned code) in the biobank at Medicine 
Institution, Karolinska University Hospital. 
Patients’ data were handled anonymously by using codes and numbers.  
The access to each patients’ journal was approved by the patients and just authorized doctors 
reviewed medical files. Access to the database was limited to researchers involved in the 
studies and it was protected by a password. 
All the studies included in this thesis are observational and descriptive, none experimental. 
For paper II different registers have been used to collect patients’ information: the National 
quality registry SWEDEHEART (www.swedeheart.se), which includes all consenting 
patients when diagnosed with MI, the Swedish Register for myocardial infarctions (RIKS-
HIA) at time of hospitalization, the Swedish register for secondary prevention (SEPHIA) at 
the secondary prevention follow-up visit 6-10 weeks post-MI, a Register for coronary-
angiography and angioplastics (SCAAR), a Coronary-Bypass Register (CABG), and a 
Register for causes of Death. The Swedish population Registry was used for controls. 
Samples from paper IV were collected in France at the Biological Resources Center, 
Assistance Publique - Hôpitaux de Marseille as part of other research projects in coagulation. 
They were sent to Sweden after authorization of the French Minister and further analysed in 
Kalmar and Uppsala, without having access to patients’ information here in Sweden. 
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4   RESULTS 
4.1 Paper I 
The levels of TAFI and TAFIa, expressed as mean±SD, are higher in APS patients compared 
to healthy controls (TAFI 111.1±18.2% n=50 APS vs 88.0±16.1% n=15 controls, p<0.0001; 
TAFIa 18.8±11.6 ng/ml n=52 APS vs 12.3±2.7 ng/ml n=15 controls, p=0.02). CLT is 
prolonged and Ks is lower in APS, indicating reduced clot permeability (CLT 1698.1±453.0 
sec n=50 APS vs 1452.2±459.4 sec n=15 controls, p=0.04; Ks 7.2±3.3 cm2x10-9 n=44 APS 
vs 9.8±2.4 cm2x10-9 n=15 controls, p=0.004). Fibrinogen and C5a are increased (fibrinogen 
4.0±0.9 g/L n=52 vs 2.7±0.5 g/L n=15, p<.0001; C5a 34.3±7.0 ng/ml n=52 vs 27.2±5.3 
ng/ml n=15, p=0.001).  
The levels of TAFIa (25.4±13.9 ng/ml arterial n=16 vs 15.8±9.1 ng/ml others n=36, 
p=0.001) and fibrinogen (4.3±0.8 ng/ml arterial n=16 vs 3.8±0.9 ng/ml others n=36, p=0.03) 
are higher in APS patients affected by arterial thrombosis compared to the levels in patients 
with other clinical manifestations. Traditional cardiovascular risk factors are present in 
higher extent as well (age p<.0001, hypertension p=0.0005, actual smoking p=0.03, 
hyperlipidemia p=0.03). More patients affected by arterial thrombosis are treated with statins 
and ACE-inhibitors/Angiotensin Receptor Blockers, as part of secondary prevention.  
TAFI positively correlates to C5a (p=0.0026, r=0.41) and age (p=0.003, r=0.41), TAFIa to 
TM (p<.0001, r=0.62) and age (p<.0001, r=0.62). TAFI and TAFIa positively correlate with 
each other (p=0.0011, r=0.45). Age and TM are the major determinants of TAFIa (p<.0001, 
R2adj=0.72; p<.0001 for age, p=0.005 for TM, p=0.004 for Ks, p=0.04 for fibrinogen). 
Patients affected by hypertension have higher levels of TAFIa compared with normotensive 
patients (25.4±13.6 ng/ml n=20 hypertensive vs 14.7±7.8 ng/ml n=32 normotensive, 
p=0.0001), but probably these data are confounded by age (hypertensive patients are older 
than normotensive: 55 vs 38 years, p<.0001). Hypertensive patients have also higher levels of 
TM (6369.5±1906.8 ng/ml n=19 vs 5230.6±2903.9 ng/ml n=31, p=0.02), but in this case TM 
does not correlate with age. TAFIa positively correlates with Ks (p=0.01, r=0.39) but not with 
CLT. Ks does not correlate with age, nor with TM, fibrinogen, cholesterol. TAFI does not 
correlate with neither CLT nor Ks. Fibrinogen positively correlate with both TAFI (p<.0001, 
r=0.61) and TAFIa (p=0.0001, r=0.50). After adjustment for age, C5a and fibrinogen remain 
associated with TAFI (p<.0001, R2adj=0.48; p=0.01 for age, p=0.003 for C5a, p=0.0009 for 
fibrinogen). There are no differences in markers of fibrinolysis according to clinical APS 
manifestations, but patients treated with heparin have higher Ks compared to others (10.6 
±3.4 cm2x10-9 n=5 vs 6.8±3.1 cm2x10-9 n=39, p=0.018). A negative correlation is present 
between TAFIa and levels if IgG aPL (p=0.028, r=0.32), but not with other isotypes. IgG aPL 
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titers are lower in patients affected by arterial thrombosis (10.7±2.0 μg/ml n=16 vs 13.1±4.3 
μg/ml n=34, p=0.04), but lose their significance when put into a multivariable model with 
TAFIa as dependent variable. 
4.2 Paper II 
IgG aCL and IgG anti-β2GPI (positivity in any of these is referred to IgG aPL) are more 
prevalent in first MI patients at 6-10 weeks post-MI compared to matched controls (11.1% vs 
1.3%, p<.0001), with no difference in the other aPL isotypes (IgM and IgA). The majority of 
IgG aPL positive first-time MI patients presented with high titers.  
Each isotype of the two different target antigens (aCL and anti-β2GPI) present a strong 
positive correlation: IgG (ρ=0.88, r=0.98, p<.0001), IgA (ρ=0.85, r=0.98, p<.0001), IgM 
(ρ=0.91, r=0.97, p<.0001). None of the investigated specificities of antinuclear antibodies 
(ANA) differ between patients and controls. 
Present smoking, family history of cardiovascular disease (CVD), but also rheumatic and 
pulmonary diseases are more common in MI patients, whereas hypertension, Body Mass 
Index (BMI) and diabetes do not differ from matched controls.  
After multivariable conditional logistic regression analysis, IgG aPL positivity [OR 7.8 (95% 
CI: 4.0-15.3), p<0.001] and present smoking [OR 2.6 (95% CI: 1.9-3.5), p<0.001] remain 
associated with MI, not so for diabetes, hypertension, BMI or family history of CVD.  
When comparing IgG aPL+ (n=88) vs IgG aPL- (n=704) MI patients, IgG aPL positivity is 
non-significantly more prevalent among females (26.1 vs. 17.9%, p=0.06) and smokers 
(33.7% vs. 25.1%, p=0.08), and significantly more prevalent in patients affected by 
pulmonary disease, in particular chronic obstructive pulmonary disease (COPD). Age (63.1 
years in IgG aPL+ vs. 61.8 years in IgG aPL-, p=0.146), presence of diabetes or rheumatic 
diseases, BMI, previous venous or arterial thrombosis, family history of CVD, or even MI 
characteristics (STEMI vs NSTEMI) do not differ between IgG aPL+ vs IgG aPL- MI.  





Table 1 – paper II 
Clinical and serological characteristics in patients with myocardial infarction IgG aPL+ vs IgG aPL- 
Characteristics IgG aPL + MI 
(n=88) 
IgG aPL - MI 
(n=704) 
p-value 
Traditional cardiovascular risk factors 
 
 
Mean age (SD), years 63 (6) 62 (8) 0.11 
Gender, female (%) 23/88 (26.1) 126/704 (17.9) 0.06 
Present smokers (%) 29/86 (33.7) 173/690 (25.1) 0.08 
Hypertension (%) 25/87 (28.7) 258/702 (36.7) 0.14 
Mean BMI (SD), kg/m2 27.4 (4.7) 27.0 (3.7) 0.35 
Diabetes (%) 10/87 (11.5) 70/702 (10.0) 0.70 
Family history of known CVD (%) 29/78 (37.2) 266/607 (43.8) 0.26 
Medical history (self-reported), (%)    
Venous thrombosis 2/88 (2.3) 25/704 (3.6) 0.76 
Stroke 1/88 (1.1) 21/701 (3.0) 0.50 
Peripheral artery disease 2/88 (2.3) 16/704 (2.3) 1 
Cancer 7/88 (8.0) 56/704 (8.0) 1 
Osteoarthritis 9/88 (10) 64/704 (9) 0.73 
Any Rheumatic diseases 24/88 (27.3) 152/704 (21.6) 0.23 
Systemic Lupus Erythematosus 0 (0) 0 (0) na 
Rheumatoid arthritis 2/88 (2.3) 13/704 (1.8) 0.68 
Psoriatic arthritis 5/88 (5.7) 37/704 (5.3) 0.80 
Pulmonary disease (any) 23/88 (26.1) 100/704 (14.2) 0.0036 
COPD 8/88 (9.1) 26/704 (3.7) 0.0185 
Asthma 7/88 (7.9) 31/704 (4.4) 0.14 
Laboratory results, mean (SD) ‡    
Total cholesterol, mmol/L 3.9 (1.0) 3.9 (0.8) 0.49 
HDL, mmol/L 1.2 (0.4) 1.2 (0.3) 0.61 
Total/HDL cholesterol ratio 3.3 (0.9) 3.3 (0.9) 0.93 
Triglycerides, mmol/L 1.3 (0.7) 1.3 (0.9) 0.54 
hsCRP, nmol/L 2.3 (2.4) 2.2 (2.7) 0.71 
Fibrinogen, g/L 3.4 (1.0) 3.4 (0.8) 0.84 
Creatinine, mol/L 80.3 (16.8) 83.6 (21.3) 0.08 
Hemoglobin, g/L 142.4 (10.9) 141.7 (11.4) 0.60 
Platelets, x109 cells/L 234.8 (49.5) 240.1 (64.8) 0.46 
Leukocytes, x109 cells/L 7.8 (11.0) 6.5 (3.4) 0.56 
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Autoantibodies targeting, (%)    
2GPI IgG+ 83/88 (94.3) 0 (0) <0.001 
2GPI IgM+ 5/87 (5.7) 4/704 (0.6) 0.0013 
2GPI IgA+ 8/88 (9.1) 4/704 (0.6) <.0001 
CL IgG+ 86/88 (97.7) 0 (0) <.0001 
CL IgM+ 4/87 (4.6) 7/704 (1.0) 0.0246 
CL IgA+ 8/88 (9.1) 4/704 (0.6) <.0001 
dsDNA+ 2/87 (2.3) 13/683 (1.9) 0.68 
Sm+ 0 (0) 1/702 (0.1) na 
Ribosomal P+ 0 (0) 0 (0) na 
RNP 68+ 0 (0) 1/702 (0.1) 1 
RNP A+ 3/88 (3.4) 27/702 (3.8) 1 
SSA Ro52+ 3/88 (3.4) 8/702 (1.1) 0.11 
SSA Ro60+ 3/88 (3.4) 6/702 (0.85) 0.07 
SSB+ 2/88 (2.3) 8/702 (1.1) 0.31 
 
‡ samples were analyzed 6-10 weeks after MI: results could be affected by the post-MI treatment 
2GPI= 2 glycoprotein I, aPL= antiphospholipid antibodies, BMI= Body Mass Index, CL= 
cardiolipin, COPD= Chronic Obstructive Pulmonary Disease, CVD= Cardiovascular Disease, HDL= 
high-density lipoproteins, dsDNA= double stranded DNA, Sm= Smith antigen, RNP= 
ribonucleoprotein, SSA= Sjögren antigen A, SSB= Sjögren antigen B, na= not applicable 
 
4.3 Paper III 
C4BPt is 20-23% lower in patients with repeated positivity for aPL, independently of 
previous thrombotic events or nephritis, as well as in patients treated with warfarin.  
No difference is present according to double or triple positivity for aPL (mean 168.5 mg/L, 
n=97 TP vs 173.9 mg/L, n=103 non-TP, p=0.23), neither depending on aPL titers or isotype. 
There are no statistically significant differences in the levels of C4BPt between arterial, 
venous and obstetric complications in either pAPS or sAPS. Similar results are found also 
when considering just patients not treated with warfarin, where the difference in C4BPt 
levels is further reduced (table 1). In general, obstetric pAPS patients tend to have higher 
levels of C4BPt compared to other groups, and they are less often treated with warfarin 
(approximately 10% of obstetric APS patients are treated with warfarin vs 50-60% of arterial 
or venous APS). aPL carriers present only a slight reduction in C4BPt compared to pAPS 
(mean 202.1 mg/L vs 175.9 mg/L), although not significantly different (p=0.8). When we 
consider the subgroups of pAPS and SLE-aPL++ not on warfarin, they present higher levels 
of C4BPt compared to the whole group (that includes also warfarin treated patients), but still 
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lower than controls (table 2). These observations further support that warfarin contributes to 
the reduced levels of C4BPt.  
Complement proteins in disease subtypes and controls 
C1q, C4, C3 are decreased in all SLE patients, with lower levels in SLE-aPL++ versus SLE-
aPL- and controls. C1q is reduced in pAPS vs matched controls (mean 237.2 mg/L vs 267.5 
mg/L, p=0.003).  
sC5b-9 is increased in pAPS, SLE-aPL++ and aPL- patients compared to controls. 
C3dg is increased in SLE-aPL++ versus SLE-aPL-, as well as in warfarin treated patients 
(9.0 μg/L on warfarin n=36 vs 6.2 μg/L not on warfarin n=245, p=0.0003). 
C4BPt and complement proteins 
C4BPt positively correlates with C1q and complement inhibitor Factor I in all subjects, and 
with C3, C4 (and C2 in SLE – not tested in controls), in SLE patients and controls. FI levels 
are not associated with aPL++ or with warfarin treatment. 
C4BPt negatively correlates with complement activation product C3dg in both SLE groups.  
C4BPt and treatment 
C4BPt is lower in pAPS and SLE-aPL++ patients treated with warfarin, compared to patients 
not on warfarin.  
On the other hand, C4BPt is higher in pAPS patients treated with LMWH as compared to 
non-treated patients, after excluding those treated with warfarin.  
No difference in C4BPt according to Low dose Aspirin (LDA) treatment was recorded. 
In SLE, C4BPt is not associated with treatment with prednisolone and its dosage, 
mycophenolate mophetil, hydroxycloroquine, metotrexate, rituximab and cyclophosphamide. 
SLE patients treated with azathioprine (AZA) have lower levels of C4BPt (161.5 (219.0-
127.5) mg/L on AZA n=32 vs 186.3 (251.1-147.6) mg/L not on AZA n=154, p=0.0221). 
Protein S in pAPS 
Both free and bound Protein S (PS) in pAPS correlate positively with C4BPt and both are 
reduced by warfarin. C4BPt, free and total PS are lower in pAPS patients affected by DVT 
compared to other clinical manifestations as previously defined. Total PS is also increased in 
patients treated with LMWH compared to non-treated pAPS, with no significant difference 
in free PS.  
Relative contribution of aPL++ and warfarin to depressed levels of C4BPt  
C4BPt is 20% reduced in SLE-aPL++ compared to SLE-aPL- and in pAPS compared to 
controls, 23% in SLE-aPL++ compared to controls. Applying mediation analysis to the SLE 
group, we assess that 45% of this reduction is mediated through warfarin. More specifically, 
aPL++ has a direct reducing effect on C4BPt of 11%, while warfarin contributes to 9% of the 
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observed reduction. An interaction effect between aPL++ and warfarin seems to be present, 
but it does not reach statistical significance.  
Table 1 – paper III 










































C4BPt 236.2 ± 115.5 0.97 
241.9 ± 
134.4 










































C4BPt 212.7 ± 67.8 0.7 208.6 ± 65.6 0.8 221.6 ± 64.2* 0.6 
 
* Calculations are made on the pure obstetric APS patients vs other clinical APS manifestations (i.e. 
when a patient has an overlap obstetric + arterial or venous, we consider it arterial or venous).  
‡ Overlap obstetric + arterial or venous 
In case of overlap arterial + venous, patients are considered alternatively arterial or venous in a total 
equal amount. The number of patients reported in each group is the total number of patients affected 
by that specific clinical APS manifestation. Conversely, mean and SD are those that have been used to 
run the t-test, and not those of all the patients with the named event because, in case of overlap, the 
patients were considered in either one or the other group/clinical APS manifestation  
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Table 2 – paper III 
Direct comparisons of C4BPt levels, expressed in mg/L, between: a) pAPS and SLE-aPL++ 
not on warfarin vs controls, b) pAPS, SLE-aPL++ and aPL carriers not on warfarin vs controls, 
c) pAPS not on warfarin vs controls, d) pAPS not on warfarin vs matched controls, e) SLE-
aPL++ not on warfarin vs controls. The independent t-test on lnC4BPt was used in a), b), c), 
e), paired t-test in d) 
a) NOT on warfarin pAPS and SLE-aPL++ (n=114) Controls (n=321) p-value 
C4BPt 206.9 ± 78.8 226.8 ± 63.4 0.0008 
b) NOT on warfarin 
pAPS, SLE-aPL++ and aPL 
carriers (n=127) 
Controls (n=321) p-value 
C4BPt 212.1 ± 85.0 226.8 ± 63.4 0.0038 
c) NOT on warfarin pAPS (n=34) Controls (n=321) p-value 
C4BPt 217.1 ± 64.3 226.8 ± 63.4 0.4 




C4BPt 217.1 ± 64.3 220.5 ± 50.9 0.7 
e) NOT on warfarin SLE-aPL++ (n=80) Controls (n=321) p-value 
C4BPt 202.6 ± 84.2 226.8 ± 63.4 0.0003 
 
4.4 Paper IV 
Thrombin generation and coagulation 
Both investigated classes of anticoagulants (warfarin and DOACs) suppress the endogenous 
thrombin generation potential (ETP), although warfarin is more effective (p<.0001). 
Warfarin also reduces the levels of D-dimer, prothrombin, protein C, protein S and 
thrombospondin. fVIII is reduced in both treatment groups. Platelets are higher in warfarin 
compared to DOACs. 
Complement activation markers 
During warfarin treatment, C1q is reduced (consumed), C3a (also presented as C3a/C3) and 
sC5b-9 are greatly increased, C4BP, both total and in complex with protein S (C4BPβ+ and 
PS-C4BPβ+), is reduced, compared to after treatment. 
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When comparing on versus off DOACs, no difference is seen in complement activation 
markers. 
When comparing the two treatments, C1q is reduced, C3a (also presented as C3a/C3) and 
sC5b-9 are increased in the warfarin treated group, whereas no difference is seen in C4BP, 
both total and as PS-C4BPβ+. However, a significant difference is seen after treatment, when 
levels of C4BPt and PS-C4BPβ+ are higher in patients previously treated with warfarin 
compared to those who received DOACs. C3a and sC5b-9 remain higher in patients post-
warfarin treatment compared to post-DOACs. The Classical Pathway (CP) functional test is 
not affected by treatment.  
Univariate and multivariate regression analysis 
There is a weak positive correlation between platelets and C3a in all treated patients 
combined (p=0.0013, r = 0.43), and in patients on warfarin treatment (p=0.0213, r = 0.45), 
but not in the DOAC treated group.  
In all treated patients taken together, free PS has a negative correlation with sC5b-9 
(p<.0001, r = -0.75) 
We observe weak inverse correlations between C1q and C3a (p=0.0033, r= -0.39), and 
between C1q and sC5b-9 (p<.0001, r = -0.50). 
Platelets, free PS and C1q are no longer significantly associated to C3a or sC5b-9 in a 
multivariable model that includes treatment group. 
C3a levels are associated with treatment (higher in warfarin treated group), sex (higher in 
women) and sC5b-9 (p<.0001, R2 adj 0.74; p=0.0002 for treatment, p=0.0263 for sex and 
p=0.0281 for sC5b-9). The higher levels in women are explained by treatment (more women 
on warfarin compared to DOACs, 64% vs 36%). In fact, there is no difference between men 
and women in C3a levels (and also C1q and sC5b-9) when taking each treatment group 
separately (treatment stratification). C3a positively correlates with sC5b-9 (p<.0001, r = 
0.82), in all treated patients. 
C4BPβ+ and PS-C4BPβ+ 
C4BPβ+ positively correlates with PS-C4BPβ+ in all patients off treatment (p<.0001, r = 
0.63), on treatment (p<.0001, r = 0.69), just on warfarin (p = 0.0202, r = 0.46), just on 
DOACs (p<.0001, r = 0.93), and off DOACs (p<.0001, r = 0.81).  
C4BPβ+ positively correlates with sC5b-9 (p<.0001, r = 0.50), and with C3a (p=0.0004, r = 
0.45) after, but not during treatment, and just when taking all patients together. 
C4BPβ+ positively correlates with number of days between drug withdrawal and sample 2 
(p= 0.0057, r = 0.61): the more time passes, the higher the levels. C3a, C5b-9, C4BPt are not 




5.1 Paper I 
In order to understand the effect of TAFI and TAFIa in APS, markers of fibrinolysis and 
complement activation should be investigated as well, since TAFIa influences both. No 
study so far has included these variables. With this study we are able to confirm that APS 
patients have a lower clot permeability and prolonged CLT as compared to healthy 
controls, in line with Vikerfors et al189. We tried to identify a possible biomarker that could 
be associated with this impaired fibrinolysis. Since TAFIa is a natural fibrinolysis inhibitor 
that also plays a role in complement regulation, we hypothesized that it could be 
associated with markers of fibrinolysis, but no association was found. Nevertheless, we 
were able to demonstrate an increased complement activation and subclinical 
inflammation present in pAPS by showing higher levels of C5a, fibrinogen, TAFI and 
TAFIa compared to controls.  
When we divided our sample according to clinical APS manifestations, we became soon 
aware that patients affected by arterial thrombotic events have higher levels of TAFIa, 
fibrinogen and TM compared to patients with other clinical APS manifestations. They also 
have more traditional CV risk factors, as expected.  
APS thromboembolism can happen at any site in the vascular tree and there is no strict 
concordance between arterial or venous thrombosis at diagnosis and that of the recurrent 
thrombotic event. So far, no biomarker has been found to be able to precisely predict which 
vessel would be hit by thromboembolism in the course of APS, or which APS manifestation 
would characterize each and every patient. We identify TAFIa levels as higher in arterial 
thrombosis, and positively associated with TM, a marker of endothelial 
damage/activation114,404. We partly confirm previous findings by Ieko et al219 of an inverse 
correlation between IgG aPL titers and TAFIa, but since we didn’t compare our cohort with a 
group of patients APS-negative and affected by another autoimmune disease, we couldn’t 
draw any other conclusion. We observe slightly lower titers of IgG aPL in the arterial 
subgroup but, after running a multivariable analysis in the whole cohort with TAFIa as the 
dependent variable, we see that they lose significance. Unfortunately, it was not possible to 
run a multivariable analysis in the arterial subgroup only, due to the small sample size.  
5.2 Paper II 
Thanks to the large PAROKRANK cohort, the SWEDEHEART quality registry and the 
Swedish population registry, we were able to collect data from a large number of patients 
from the general population affected by a first time MI, well matched with controls free from 
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previous MI and heart valve replacements. A strong association is shown between IgG aPL 
and first-time MI, independently of traditional CV risk factors. We confirm previous reports 
that the IgG aPL isotype is more strongly associated with occlusive vascular events than IgM 
or IgA aPL253,405,406. We cannot confirm the findings by Bili et al255, that patients belonging to 
the lowest quartile of IgM anti-CL are at increased risk of recurrent cardiac events. Moreover, 
previous studies243,257-259 suggest that aPL are overrepresented in young patients with MI. 
Considering the present data, obtained from a population with a mean age of 62 years, this 
assumption may need some revision towards accepting aPL positivity as a potential risk 
factor also in older age groups. The fact that IgG aPL+ MI patients tend to be smokers more 
often than controls, although not significantly, is in line with previous reports on positive 
associations between aPL and smoking47,257,259,406. This observation may also explain the 
positive association between Chronic Obstructive Pulmonary Disease (COPD), a proxy for 
smoking habits, and IgG aPL.  
This study is important because it demonstrates that aPL are common in patients with MI in 
the general population. Our results create the premises for a follow-up study where, by 
repeating aPL measurement and comparing outcomes, we will be able to establish if aPL are 
transient or permanent, if isotypes differ or switch during long-term observations and if they 
have prognostic significance. These findings may have an impact on treatment, because, in 
case of persistent aPL positivity, patients should receive indefinite anticoagulants, according 
to the present APS guidelines362, thus changing the current screening and treatment strategies 
for patients with MI at coronary care units.  
5.3 Paper III 
Our findings demonstrate that levels of complement inhibitor C4BPt are depressed in 
persons with persistent presence of aPL as compared to aPL negative subjects, irrespective of 
underlying SLE, lupus nephritis, thrombotic manifestations or aPL profile. Further 
reductions of C4BPt are seen in patients who are treated with warfarin, whereas higher levels 
are present in patients treated with LMWH. There are no statistically significant differences 
in the levels of C4BPt between arterial, venous and obstetric complications in either pAPS or 
sAPS, although obstetric pAPS patients tend to have higher levels compared to other groups. 
This may be explained by the fact that they are less often treated with warfarin 
(approximately 10% of obstetric pAPS patients are on warfarin vs 50-60% of patients with 
previous arterial or venous thrombotic events). In the same way, aPL carriers present only a 
slight and non-significant reduction in C4BPt as compared to controls, because they are less 
often treated with warfarin. Among aPL carriers 2/15 (13%) are on warfarin as compared to 
the other groups of aPL++ with pAPS or SLE (50% and 34% respectively on warfarin). 
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Therefore, infrequent warfarin use may explain why we observe less C4BPt reduction in aPL 
carriers and in obstetric pAPS.  
Moreover, low C4BPt levels are associated with markers of enhanced complement activation 
(C2, C3, C4, and negatively with C3dg), indicating that the reduction of C4BPt may have a 
functional impact. We also measured free and total protein S in pAPS, showing lower levels 
of both fractions in warfarin treated patients, in the subgroup affected by DVT (more often 
treated with warfarin) and in correlation to C4BPt.  
This work can have a considerable impact in the research field of APS and SLE, not only for 
the observation that C4BPt is depressed in patients with aPL++/APS, but especially for the 
observed effects of anticoagulation on the complement system, an aspect that has not been 
taken into account in the majority of the studies so far. If C4BP is reduced in warfarin-treated 
patients and in aPL+, does this lead to complement activation? Or maybe other complement 
inhibitors are upregulated to compensate for the C4BP reduction? Is the complement 
activation that was reported in previous APS studies, due also to anticoagulant treatment 
with warfarin? What about the C4d deposits on platelets or erythrocytes? Are they an effect 
of C4BP reduction or a secondary effect of warfarin? If this is the case, the results of many 
studies on APS and complement done so far should be reconsidered.   
5.4 Paper IV 
This study is important in general for patients in need of anticoagulant treatment, and in 
particular for APS patients. We demonstrate for the first time that warfarin, in contrast to 
DOACs, is strongly associated with markers of complement activation (increased levels of 
C3a and sC5b-9, consumption of C1q), not only during the actual treatment but also 2-3 
weeks after withdrawal.  
What was already known by previous studies in the general population342,348,349,360, confirmed 
in aPL++ patients in paper III407, was that warfarin reduces C4BP. This study adds that levels 
of C4BPt and PS-C4BPβ+ become higher after warfarin withdrawal, as a rebound effect, and 
remain persistently high for at least 19 days on average. Also C3a and sC5b-9 remain higher 
post-warfarin compared to post-DOACs, positively correlating to C4BPβ+.  
We are able to clarify that DOACs have no effect on complement, but, in contrast, we 
demonstrate that warfarin is associated with complement activation, partly but probably not 
only through inhibition of C4BP. 
These results give new perspectives, possibly of importance for the choice of anticoagulants, 




5.5 Limitations and strengths 
5.5.1 Limitations 
The three first studies are cross-sectional, a study design that does not allow to infer causality 
because it presents just a moment in time, not showing the temporal relationship between the 
measured variables. This is of particular relevance for paper II, where we cannot provide 
information about the presence of aPL before the MI event, or know if aPL developed as a 
response to myocardial damage, making it impossible to infer causality. Nevertheless, we 
know that the frequency of previous venous and arterial thromboses is not higher in the aPL+ 
MI compared to the aPL- subset. The samples were taken just once at 6-10 weeks post-MI, 
so aPL cannot be characterized as transient or permanent. For the same reason, the observed 
differences between MI patients and controls regarding lipids and blood pressure levels are 
not reliable for comparison, because they are all affected by post-MI treatment. 
In all papers, the samples were collected in a quiescent phase of APS. Thus, we don’t know 
how TAFIa, TM, C5a and markers of fibrinolysis (paper I) behave at the time of an acute 
thrombosis, e.g. MI (paper II). We even don’t know how C4BPt (paper III and IV) changes 
or relates to aPL profile/complement activation markers during acute phases of 
thrombotic/obstetric events. 
The small number of patients in paper I and IV is a limitation: if we had more patients, we 
would have had more power to run a multivariable analysis just in the arterial subset of 
patients (paper I). The lack of a significant difference in C4BP levels during treatment with 
warfarin versus DOACs in paper IV may be due to lack of power.   
Finally, not having enough samples: in paper II, due to lack of citrated plasma, the LA test 
could not be performed, and in paper III we couldn’t measure PS in controls, so that we 
lacked a reference group, as well as in SLE patients, which prevented us from running a 
mediation analysis to quantify the direct and controlled effect of aPL++ by warfarin on PS 
reduction. The lack of samples from controls free from thrombosis and its treatment in paper 
IV precluded us the possibility to compare C4BP and complement factors in patients on/off 





Patients from studies I and III are well characterized and they fulfill Miyakis criteria for 
primary or secondary APS2. aPL are determined according to standardized cut-offs and 
detection methods. 
The main strength of paper I is the fact that we studied well-characterized, mostly pAPS 
patients, free from SLE. We investigated TAFI and TAFIa also in relation to CLT, Ks and 
markers of complement activation, and analyzed these molecules separately in different 
clinical APS manifestations.  
The number of subjects studied in paper II is large and representative of both sexes, with a 
broad age-span, including well-matched controls, with an extensive collection of patients’ 
characteristics. All events were first-time MIs. aPL are also differentiated according to 
isotype and target antigen, and that allowed us to demonstrate the unique association of IgG 
aPL with first-time MI, whereas we didn’t see any association with the other isotypes, as 
well as the strong correlation between the same isotype of different target antigens (aCL and 
anti-β2GPI). In previous studies, IgG was either analyzed in isolation
408,409 or pooled with 
IgM410,411, making it difficult to dissect the role of each isotype. 
Also in paper III, considering the rarity of APS/aPL++, we were able to study a relatively 
large number of subjects, who were well characterized regarding their clinical manifestations 
and aPL profiles, representing both primary and secondary APS and aPL carriers. We also 
investigated a large number of complement proteins representing different steps in the 
classical pathway of the complement cascade. 
Thanks to the study design in paper IV, we could limit bias by studying the same patients 
during and after treatment. 
Paper II, despite having, at present, a cross-sectional design, it has the potential to become a 
large longitudinal study, thanks to an already planned follow-up of the same subjects. 
All the four studies presented in this thesis try to answer crucial questions in APS by 
analyzing known proteins (TAFI, C4BP, complement factors): 
 in a relatively new group of patients: well characterized APS, precisely sub-
classified according to more recent criteria 
 in relation to old and new anticoagulant treatments 
 by studying the prevalence of aPL positivity of different isotypes in a large cohort 




6 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
6.1 Conclusions 
 TAFI and TAFIa are increased in pAPS 
 TAFIa is particularly increased in patients with pAPS affected by arterial thrombosis, 
independently of traditional CV risk factors 
 Thrombomodulin, a marker of endothelial damage/activation, is increased in pAPS 
patients affected by arterial thrombosis, and positively correlates with TAFIa 
 There is a subclinical inflammation in patients with pAPS, marked by higher levels 
of TAFI and complement activation 
 pAPS patients have an impaired fibrinolysis, measured by a prolonged CLT and 
lower permeability coefficient Ks 
 There is a detectable complement activation in APS: higher levels of C5a, C3a, 
C3dg, sC5b-9, and consumed C1q 
 The complement inhibitor C4BP is reduced by both warfarin treatment and 
persistently positive aPL 
 Warfarin, DOACs and LMWH have a different impact on the complement system 
and C4BP 
 6-10 weeks after a first-time MI, the prevalence of IgG aPL is 11%, i.e. ten times 
higher as compared to matched controls 
 
6.2 Future perspectives 
 Longitudinal follow-up study of paper II, to explore the prognostic value of IgG aPL 
in patients with MI (now being performed) 
 Personal follow-up with new measurements of aPL in patients who were aPL 
positive after their first MI, to investigate if aPL are persistent after 6-10 years 
 Measure plasma C4d in SLE/APS in relation to anticoagulant treatment and C4BP 
levels 
 Measure C4d deposits on platelets or in kidney biopsies in primary and secondary 
APS, also in relation to anticoagulant treatment and C4BP levels 
 Measure antibodies against C4BP in APS 
 Further studies on the effects of warfarin on the complement system 
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